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Abstract		DNA	end	resection	initiates	the	repair	of	DNA	breaks	by	homologous	recombination.	The	MRE11-RAD50-NBS1	and	phosphorylated	CtIP	perform	the	first	resection	step	by	MRE11-catalyzed	endonucleolytic	DNA	cleavage.	Human	NBS1,	unlike	its	homologue	from	Saccharomyces	cerevisiae,	is	crucial	for	this	process,	highlighting	complex	mecha-nisms	that	regulate	the	MRE11	nuclease	in	high	eukaryotes.	Using	a	reconstituted	sys-tem,	we	show	here	that	NBS1,	through	its	FHA	and	BRCT	domains,	functions	as	a	sensor	of	CtIP	phosphorylation.	NBS1	then	activates	the	MRE11-RAD50	nuclease	through	direct	physical	interactions	with	MRE11.	In	the	absence	of	NBS1,	MRE11-RAD50	exhibits	a	weaker	nuclease	activity,	which	requires	CtIP	but	is	not	strictly	dependent	on	its	phos-phorylation.	This	identifies	at	least	two	mechanisms	how	CtIP	promotes	MRE11:	a	phos-phorylation-dependent	mode	through	NBS1,	and	a	phosphorylation-independent	in	the	absence	of	NBS1.	In	support,	we	show	that	limited	DNA	end	resection	in	the	absence	of	the	FHA	and	BRCT	domains	of	NBS1	occurs	in	vivo.	Collectively,	our	data	suggest	that	NBS1	restricts	the	MRE11-RAD50	nuclease	to	S-G2	phase	when	CtIP	is	extensively	phos-phorylated.	This	defines	mechanisms	that	regulate	the	MRE11	nuclease	in	DNA	metabo-lism.	
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Introduction		The	maintenance	of	genomic	integrity	is	critically	important	as	cells	are	constantly	ex-posed	to	various	genotoxic	agents.	DNA	double-strand	breaks	(DSBs)	represent	a	very	deleterious	lesion	that	is	difficult	to	repair	due	to	the	loss	of	genetic	information	in	both	DNA	strands.	While	unrepaired	DSBs	may	result	in	cell	death,	their	inaccurate	repair	can	lead	to	mutagenesis	and	inappropriate	chromosomal	translocations	(Ranjha	et	al.,	2018).	Cells	possess	two	main	mechanisms	for	DSB	repair:	end-joining	pathways	includ-ing	Ku-dependent	non-homologous	end-joining	(NHEJ)	and	Ku-independent	microho-mology-mediated	end-joining	(MMEJ),	which	are	functional	in	any	phase	of	the	cell	cycle	and	do	not	require	a	DNA	template	(Ranjha	et	al.,	2018).	The	second	mechanism	is	tem-plate-dependent	homologous	recombination	(HR),	which	is	generally	restricted	to	the	S-G2	phase	of	the	cell	cycle.	The	sister	chromatid	serves	as	an	HR	template	in	most	cases	in	vegetative	cells,	explaining	why	recombination	can	only	function	in	the	cell	cycle	phases	when	sister	chromatids	are	available	(Ranjha	et	al.,	2018).	This	is	achieved	by	a	regulatory	mechanism	involving	cyclin-dependent	kinases	(CDKs),	which	phosphorylate	key	factors	that	function	in	the	first	step	in	the	HR	pathway	termed	DNA	end	resection	(Huertas	et	al.,	2008;	Huertas	and	Jackson,	2009).	Resection	involves	nucleolytic	degra-dation	of	the	5'-terminated	DNA	strand	at	DSBs,	leading	to	3'-overhangs	that	are	essen-tial	for	the	downstream	steps	in	the	recombination	pathway.	While	limited	DNA	end	re-section	may	be	involved	in	MMEJ,	DNA	that	underwent	extended	resection	is	no	longer	ligatable	and	therefore	unsuitable	for	end-joining.	The	decision	whether	and	to	which	extent	to	resect	DNA	ends	therefore	regulates	the	pathway	choice	in	DSB	repair	(Ranjha	et	al.,	2018).	The	MRE11-RAD50-NBS1	(MRN,	in	human	cells)	or	Mre11-Rad50-Xrs2	(MRX,	in	yeast)	complex	has	multiple	key	evolutionarily	conserved	functions	to	initiate	and	coordinate	the	repair	of	DSBs	(Paull,	2010;	Stracker	and	Petrini,	2011).	This	includes	roles	in	both	end-joining	and	homologous	recombination	repair	pathways	(Carney	et	al.,	1998;	de	Jager	et	al.,	2001;	Moore	and	Haber,	1996;	Paull	and	Gellert,	1998,	1999;	Rass	et	al.,	2009).	Additionally,	MRN	promotes	DNA	end	tethering	and	is	required	to	signal	the	presence	of	DSBs	via	the	ATM	kinase	(Carney	et	al.,	1998;	de	Jager	et	al.,	2001;	Lee	and	Paull,	2005;	Stewart	et	al.,	1999;	Usui	et	al.,	2001;	Williams	et	al.,	2008).	This	is	achieved	by	a	conserved	interaction	between	the	MRN	subunit	NBS1	(Xrs2	in	S.	cerevisiae)	and	ATM	(Tel1	in	yeast).	ATM	in	turn	phosphorylates	hundreds	of	protein	targets	that	regu-late	the	response	to	DSBs.	Beyond	ATM,	NBS1	also	interacts	with	MDC1,	which	binds	phosphorylated	proteins	including	H2AX	(γH2AX)	to	amplify	the	DNA	damage	signaling	
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beyond	the	vicinity	of	the	DSB	(Goldberg	et	al.,	2003).	In	recombination,	the	MRN	com-plex	has	a	direct	role	in	DNA	end	resection	mediated	by	the	MRE11	nuclease	in	the	S-G2	phase	of	the	cell	cycle.	MRE11	is	likely	the	first	nuclease	to	resect	DSBs,	which	is	particu-larly	important	for	the	processing	of	breaks	with	secondary	DNA	structures	or	protein	adducts	such	as	stalled	topoisomerases	or	Ku	(Anand	et	al.,	2016;	Deshpande	et	al.,	2016;	Reginato	et	al.,	2018;	Shibata	et	al.,	2014;	Wang	et	al.,	2017).	The	current	models	posit	that	resection	by	MRE11	is	initiated	by	an	endonucleolytic	DNA	cleavage	internal	to	the	DSB	past	the	protein	block,	followed	by	3'→5'	exonucleolytic	degradation	back	to-ward	the	DNA	end	(Cannavo	and	Cejka,	2014;	Garcia	et	al.,	2011;	Keeney	and	Kleckner,	1995;	Neale	et	al.,	2005;	Shibata	et	al.,	2014).	The	endonucleolytic	cleavage	sites	also	represent	entry	sites	for	processive	DNA	end	resection	nucleases	that	function	down-stream	of	MRN	in	the	5'→3'	direction,	including	EXO1	and	DNA2	(Gravel	et	al.,	2008;	Mimitou	and	Symington,	2008;	Nimonkar	et	al.,	2011;	Zhu	et	al.,	2008).	The	MRN	nucle-ase	furthermore	likely	functions	to	promote	MMEJ	independently	of	the	cell	cycle,	which	to	date	remains	very	poorly	defined	(Deng	et	al.,	2014;	Ma	et	al.,	2003;	Rahal	et	al.,	2010;	Sharma	et	al.,	2015;	Taylor	et	al.,	2010;	Truong	et	al.,	2013).	The	processing	of	protein-blocked	DSBs	is	an	evolutionarily	conserved	capacity	of	MRE11	homologues	and	their	co-factors.	In	bacteria,	the	MRE11-RAD50-like	SbcC-SbcD	complex	endonucleotically	cleaves	DNA	near	blocked	DNA	ends	(Connelly	et	al.,	2003).	Eukaryotic	cells	possess	a	third	member	of	the	MRE11-RAD50	complex,	NBS1/Xrs2,	as	well	as	CtIP/Sae2,	which	function	as	a	co-factors	of	the	MRE11	nuclease	in	resection	(Carney	et	al.,	1998;	Sartori	et	al.,	2007).	In	S.	cerevisiae,	Sae2	phosphorylated	by	CDK	and	other	kinases	has	a	critical	function	to	promote	the	Mre11-Rad50	endonuclease	near	protein	blocks	(Cannavo	and	Cejka,	2014;	Huertas	et	al.,	2008;	Reginato	et	al.,	2018;	Wang	et	al.,	2017),	while	Xrs2	per	se	is	not	essential	for	the	DNA	clipping	reaction	(Oh	et	al.,	2016),	but	may	have	a	stimulatory	function	(Wang	et	al.,	2017).	It	has	been	demonstrated	that	Xrs2	is	responsible	for	the	nuclear	import	of	the	MRX	complex	(Carney	et	al.,	1998;	Tsukamoto	et	al.,	2005).	When	this	function	was	bypassed	by	plac-ing	the	nuclear	localization	signal	on	Mre11,	Xrs2	became	dispensable	for	the	Mre11-Rad50-dependent	functions	in	resection	also	in	vivo	(Oh	et	al.,	2016).	In	contrast,	Xrs2	
per	se	was	required	for	DNA-damage	signaling	function	of	the	MRX	complex	(Oh	et	al.,	2016).		In	humans,	both	CtIP,	when	phosphorylated	by	CDK,	and	NBS1	promote	the	MRE11-RAD50	endonuclease	(Anand	et	al.,	2016;	Deshpande	et	al.,	2016).	The	differen-tial	requirement	for	NBS1/Xrs2	between	budding	yeast	and	humans	likely	reflects	the	need	for	more	complex	regulatory	mechanisms	to	control	the	MRE11	nuclease	in	high	eukaryotes.	How	NBS1	performs	this	function	however	remains	poorly	characterized.	
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Beyond	DSB	processing,	unscheduled	DNA	degradation	by	MRE11	at	stalled	DNA	repli-cation	forks	may	be	responsible	for	the	toxicity	associated	with	defects	in	BRCA1	or	BRCA2,	further	highlighting	the	importance	to	understand	how	MRE11	nuclease	is	regu-lated	in	human	cells	(Feng	and	Jasin,	2017;	Mijic	et	al.,	2017;	Ray	Chaudhuri	et	al.,	2016;	Schlacher	et	al.,	2011).	Human	NBS1	consists	of	754	amino	acids.	The	N-terminus	contains	forkhead-associated	domain	(FHA)	and	tandem	BRCA1	C-terminal	(BRCT)	motifs	(BRCT1	and	BRCT2),	which	bind	phosphorylated	proteins	including	CtIP	and	MDC1	(Wang	et	al.,	2013;	Williams	et	al.,	2009).	At	its	C-terminal	part,	NBS1	contains	ATM	and	MRE11	interaction	sites,	as	well	as	three	potential	nuclear	localization	signals	that	promote	the	nuclear	import	of	MRN	(Carney	et	al.,	1998;	Falck	et	al.,	2005;	Nakada	et	al.,	2003;	Tsukamoto	et	al.,	2005;	You	et	al.,	2005).	The	FHA	domain	of	S.	cerevisiae	Xrs2	binds	phosphorylated	Sae2,	alt-hough	this	capacity	appears	to	be	mostly	dispensable	for	DNA	end	resection	in	vitro	and	
in	vivo	(Liang	et	al.,	2015;	Oh	et	al.,	2016).	Structural	and	biochemical	characterization	of	MRN	in	Schizosaccharomyces	pombe	revealed	that	it	also	binds	phosphorylated	Ctp1,	an	ortholog	of	CtIP/Sae2	in	S.	pombe,	through	the	FHA	motif	of	Nbs1	(Lloyd	et	al.,	2009;	Williams	et	al.,	2009).	A	point	mutation	that	affects	this	interaction	resulted	in	hyper-sensitivity	to	ionizing	radiation	and	camptothecin,	as	well	as	impaired	Ctp1	enrichment	at	DSBs	(Williams	et	al.,	2009).	Similarly	in	human	cells,	CtIP	phosphorylated	by	CDK	at	multiple	sites	in	the	center	of	the	protein	binds	the	FHA-BRCT	domains	of	NBS1,	which	is	important	for	DNA	end	resection	(Hari	et	al.,	2010;	Wang	et	al.,	2013).	However,	this	CDK-dependent	phosphorylation	was	also	important	for	the	subsequent	modification	of	T859	by	ATM	that	is	required	for	resection	in	vivo.	Phosphomimetic	T859E	could	par-tially	bypass	the	requirement	for	the	phosphorylation	of	CtIP	at	CDK	sites	that	mediate	its	interaction	with	the	FHA-BRCT	domains	of	NBS1,	raising	questions	whether	these	domains	are	required	for	resection	per	se,	or	only	serve	as	a	platform	to	help	phosphory-late	CtIP	at	T859	(Wang	et	al.,	2013).	Likewise,	mutations	in	FHA-BRCT	abrogate	the	in-teraction	of	NBS1	with	MDC1,	which	may	have	an	indirect	effect	on	resection	as	a	result	of	disrupted	signaling	(Goldberg	et	al.,	2003).	Because	of	the	multiple	functions	of	the	MRN	complex	and	potential	pleiotropic	phenotypes	associated	with	NBS1	defects,	the	interpretation	of	cell-based	resection	assays	with	NBS1	variants	is	challenging.		Here,	we	primarily	employ	in	vitro	reconstituted	reactions	to	define	the	function	of	NBS1	in	DNA	end	resection	by	MRN-CtIP.	We	show	that	both	FHA	and	BRCT	domains	of	NBS1	promote	resection	by	MRE11	through	interacting	with	phosphorylated	CtIP.	When	NBS1	senses	that	CtIP	is	phosphorylated,	it	promotes	resection	by	a	mechanism	that	is	
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dependent	on	its	interaction	with	MRE11.	This	is	in	agreement	with	a	recent	study	showing	that	an	NBS1	fragment	containing	the	MRE11	biding	site	but	not	FHA-BRCT	rescues	embryonic	lethality	of	NBS1-deficient	mice	(Kim	et	al.,	2017).	Importantly,	we	identify	an	NBS1-independent	DNA	cleavage	activity	of	MRE11-RAD50	and	CtIP.	Alt-hough	less	efficient	than	the	resection	capacity	of	the	MRN-CtIP	holocomplex,	the	NBS1-independent	activity	is	promoted	by	CtIP	but	surprisingly	does	not	require	its	phos-phorylation.	Accordingly,	we	find	limited	CtIP-	and	MRE11-dependent	but	NBS1-independent	DSB	resection	activity	in	vivo.	These	results	suggest	that	a	mechanism	that	interferes	with	the	function	of	NBS1	might	allow	limited	resection	in	the	absence	of	CDK-dependent	modification	of	CtIP,	which	might	be	relevant	for	understanding	MRE11	nuclease	functions	in	G1.					
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Results:		
NBS1	in	trans	promotes	endonucleolytic	cleavage	by	MRE11-RAD50	and	pCtIP	Previously,	we	showed	that	phosphorylated	CtIP	(pCtIP)	promotes	the	clipping	of	the	5'-terminated	DNA	strand	near	protein	blocked	DSBs	by	the	MRE11	nuclease	within	the	MRE11-RAD50-NBS1	(MRN)	complex	(Anand	et	al.,	2016).	This	reaction	is	believed	to	initiate	DNA	end	resection	by	MRN.	The	dsDNA	clipping	efficiency	of	MRE11-RAD50	(MR)	was	strongly	reduced	compared	to	MRN,	showing	that	NBS1	has	an	important	function	to	stimulate	this	activity,	in	contrast	to	its	yeast	Xrs2	homologue,	which	is	largely	dispensable	(Anand	et	al.,	2016;	Deshpande	et	al.,	2016;	Oh	et	al.,	2016).	To	de-fine	the	function	of	NBS1	in	the	regulation	of	the	MRE11	nuclease	in	the	human	system,	we	expressed	and	purified	NBS1,	as	well	as	MR,	MRN	complexes	and	pCtIP	in	Spodop-
tera	frugiperda	9	(Sf9)	insect	cells	(Figs	1A	and	EV1A-C).		NBS1	was	purified	by	affinity	chromatography	by	utilizing	maltose	binding	protein	(MBP)	and	10x	histidine	(his)	tags,	located	at	N-	and	C-termini,	respectively.	As	the	re-moval	of	the	MBP	tag	by	PreScission	protease	cleavage	was	not	very	efficient	(Fig	EV1D),	this	step	was	omitted	during	the	final	purification	(Fig	1A).	MBP-NBS1-his	added	in	trans	promoted	dsDNA	clipping	by	MR	and	pCtIP	(Fig	1B	and	C).	This	was	indistin-guishable	from	DNA	cleavage	by	pCtIP	and	MRN	purified	as	a	complex,	where	NBS1	is	untagged,	both	in	terms	of	cleavage	positions	and	efficiency	(Fig	1B	and	C).	Therefore,	the	affinity	tags	did	not	affect	the	stimulatory	function	of	NBS1	on	dsDNA	clipping	by	MR	and	pCtIP	in	vitro.	To	further	confirm	this,	we	note	that	a	treatment	of	MBP-NBS1	with	PreScission	protease,	which	cleaves	~50%	of	the	MBP	tag	off	NBS1,	did	not	affect	dsDNA	clipping	efficiency	(Fig	EV1D	and	E).	Finally,	FLAG-NBS1-his	construct	promoted	DNA	cleavage	similarly	as	MBP-NBS1-his	(Fig	EV1F	and	G).	In	summary,	we	conclude	that	MBP-NBS1-his	(hereafter	NBS1	for	brevity)	added	in	trans	promotes	the	capacity	of	MR	and	pCtIP	ensemble	to	clip	5'-terminated	DNA	in	the	vicinity	of	protein	blocks.		
FHA	and	BRCT	domains	of	NBS1	are	important	for	the	processing	of	protein	
blocked	DSBs,	while	its	interaction	with	MRE11	is	essential	NBS1	mediates	physical	interactions	of	the	MRN	complex	with	ATM,	BRCA1,	BLM,	MDC1,	CtIP	and	possibly	other	factors	(Carney	et	al.,	1998;	Chen	et	al.,	2008;	Goldberg	et	al.,	2003;	Hari	et	al.,	2010;	Spycher	et	al.,	2008;	Stewart	et	al.,	1999;	Wang	et	al.,	2013;	Wang	et	al.,	2000;	Williams	et	al.,	2008).	Out	of	these,	the	interactions	with	CtIP	and	
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MDC1	are	at	least	in	part	phosphorylation-dependent.	To	specifically	define	the	func-tional	interaction	of	NBS1	with	MR	and	pCtIP	in	resection,	we	employed	our	in	vitro	re-constituted	system	(Anand	et	al.,	2016).	To	this	point,	we	prepared	NBS1	variants	lack-ing	particular	domains	or	carrying	mutations	specifically	affecting	known	interactions	with	the	MR	and	pCtIP	ensemble	(Fig	2A	and	B),	and	assayed	them	in	nuclease	assays	to	determine	their	effect	on	the	MRE11	endonuclease.		We	first	varied	the	concentrations	of	wild	type	NBS1	in	reactions	with	MR	and	pCtIP.	While	weak	NBS1-independent	DNA	cleavage	was	observed	(Fig	2C	and	D),	we	found	that	less	than	equimolar	concentrations	of	NBS1	compared	to	the	MR	complex	were	suf-ficient	for	maximal	DNA	clipping	activity	(Fig	2C	and	D).	We	next	tested	various	NBS1	fragments	lacking	FHA,	BRCT	or	both	domains	(Figs	2E	and	EV2A).	As	phosphorylation	of	CtIP	is	required	for	resection	(Huertas	and	Jackson,	2009),	and	the	MRN	complex	pri-marily	binds	phosphorylated	CtIP	via	the	FHA	and	BRCT	domains	of	NBS1	(Figs	2F	and	G)(Wang	et	al.,	2013;	Williams	et	al.,	2009),	a	strong	defect	in	resection	was	anticipated.	As	shown	in	Fig	2E,	a	deletion	of	either	FHA	or	BRCT	domain	in	NBS1	had	only	a	minor	effect	on	resection	in	vitro,	while	elimination	of	both	domains	significantly	reduced	but	not	eliminated	resection.	Similar	effects	were	observed	with	the	NBS1	RRHK	variant,	carrying	four	point	mutations	(R28A,	R43A,	H45A	in	FHA	and	K160M	in	BRCT1,	Fig	2A)(Wang	et	al.,	2013).	The	RRHK	mutations	decreased	the	phosphorylation-dependent	interaction	of	NBS1	with	phosphorylated	MDC1	(Hari	et	al.,	2010),	as	well	as	with	pCtIP	(Fig	2F),	which	led	to	a	dramatic	DNA	end	resection	defect	in	vivo,	as	scored	by	single-strand	annealing	reporter	assay	(Hari	et	al.,	2010;	Wang	et	al.,	2013).	Despite	the	strong	physical	interaction	between	the	FHA	and	BRCT	domains	of	NBS1	and	pCtIP	(Fig	2F),	which	is	dependent	on	CtIP	phosphorylation	(Fig	2G),	we	conclude	that	both	domains	of	NBS1	are	important,	but	not	essential	for	the	DNA	clipping	activity	in	vitro	together	with	MR	and	pCtIP.	Furthermore,	NBS1	(335-754)	exhibited	similar	stimulatory	activity	to	NBS1	(622-754),	revealing	that	the	central	NBS1	region	(residues	335-621)	is	dispensa-ble	for	MR	and	pCtIP-mediated	resection,	despite	this	region	mediated	residual	interac-tion	with	pCtIP	(Fig	2E	and	F,	and	H).	It	has	been	demonstrated	that	the	MRE11-RAD50	complex	directly	interacts	with	NBS1	
via	the	MRE11-interaction	region	(MIR)	within	the	C-terminal	part	of	NBS1,	with	the	most	important	motif	located	between	residues	684-690	of	NBS1	(Desai-Mehta	et	al.,	2001;	Kim	et	al.,	2017;	Schiller	et	al.,	2012).	This	interaction	facilitates	MRN	entry	into	the	nucleus	as	only	NBS1	contains	the	nuclear	localization	sequence.	Therefore,	in	vivo	experiments	with	mutated	MIR	of	NBS1	cannot	easily	distinguish	effects	related	to	
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impaired	nuclear	entry	from	direct	effects	on	the	biochemical	activities	of	the	MR	com-plex.	Using	our	in	vitro	system,	where	any	effects	on	nuclear	import	are	irrelevant,	we	observed	that	in	contrast	to	the	FHA	and	BRCT	domains,	the	MRE11	interaction	region	in	NBS1	was	absolutely	essential	for	the	stimulatory	function	of	NBS1	on	the	MRE11-RAD50	endonuclease	in	conjunction	with	pCtIP	(Figs	2H	and	EV2B).	Specifically,	the	NBS1	(1-692)	fragment	lacking	the	very	C-terminal	region	of	NBS1,	but	possessing	MIR,	exhibited	similar	activity	as	full-length	NBS1	(Figs	2H	and	EV2A).	However,	additional	shortening	by	9	residues	comprising	MIR	(residues	684-692)	completely	eliminated	the	stimulatory	activity	(Figs	2H	and	EV2A	and	B).	Likewise,	the	internal	deletion	of	MIR	(residues	684-690)	totally	abolished	NBS1	function	in	DNA	clipping,	even	at	high	con-centrations	(Figs	2H	and	EV2B	and	C).	In	accord	with	previous	studies	(Desai-Mehta	et	al.,	2001;	Schiller	et	al.,	2012),	we	observed	a	dramatic	reduction	of	the	MRE11	and	NBS1	physical	interaction	when	NBS1	∆MIR	variant	was	used	in	pulldown	experiments	instead	of	wild	type	NBS1	(Fig	EV2D	and	E).	In	summary,	the	NBS1-dependent	interac-tion	with	MRE11-RAD50,	more	than	that	with	pCtIP,	is	important	for	the	endonuclease	activity	of	the	MRE11-RAD50	and	pCtIP	nuclease	ensemble.			
In	the	absence	of	pCtIP,	NBS1	promotes	MR	cleavage	independently	of	its	FHA	and	
BRCT	domains	Recently,	it	has	been	shown	that	NBS1	alone	is	capable	of	stimulating	the	endonucleo-lytic	activity	of	MR	on	protein-blocked	dsDNA,	independently	of	CtIP	(or	pCtIP)(Deshpande	et	al.,	2016).	Although	CtIP-independent	DNA	end	resection	does	not	likely	occur	in	vivo	(Sartori	et	al.,	2007),	we	used	the	in	vitro	assay	to	learn	more	about	the	function	of	NBS1.	To	this	point,	we	employed	our	NBS1	mutants	in	an	MR-dependent	nuclease	assay	with	streptavidin-blocked	dsDNA.	In	contrast	to	the	assays	that	included	pCtIP,	the	reactions	were	incubated	for	2	h	instead	of	30	min	to	compensate	for	the	lower	cleavage	efficacy	in	the	absence	of	pCtIP.	We	observed	that	all	NBS1	fragments	containing	MIR	stimulated	the	clipping	activity	of	MR	almost	indistinguishably,	irrespec-tively	of	FHA	and	BRCT	domains	(Figs	3A	and	B,	and	EV3A).	This	included	the	short	NBS1	(622-754)	fragment	containing	133	residues,	which	stimulated	the	endonucleo-lytic	cleavage	to	the	same	extent	as	full-length	wt	NBS1.	Conversely,	NBS1	fragments	lacking	MIR	did	not	at	all	promote	MR	(Figs	3A	and	B,	and	EV3A).	Very	similar	results	were	obtained	using	circular	ssDNA	as	a	substrate,	which	forms	a	variety	of	secondary	DNA	structures	(Fig	3C	and	D).	However,	as	noted	previously,	we	believe	that	the	cleav-age	of	dsDNA	near	protein	blocks	is	a	better	model	for	the	resection	reactions	taking	
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place	in	cells	(Fig	EV3B-F)	(Anand	et	al.,	2016;	Chen	et	al.,	2005;	Deshpande	et	al.,	2014).	In	summary,	we	show	that	in	the	absence	of	pCtIP,	the	phosphoprotein	binding	domains	of	NBS1	become	dispensable	for	resection	in	vitro.	This	supports	a	model	for	resection	in	wild	type	cells,	where	the	FHA-BRCT	domains	of	NBS1	promote	resection	by	binding	phosphorylated	CtIP,	and	NBS1	in	turn	activates	the	MR	complex	by	interacting	with	MRE11.		
BRCT	and	FHA	domains	of	NBS1	are	important	but	not	absolutely	essential	for	re-
section	in	vivo	To	verify	the	physiological	significance	of	our	data,	we	first	designed	an	NBS1	comple-mentation	system	in	U2OS	cells	to	define	the	requirement	of	the	FHA	and	BRCT	domains	of	NBS1	for	DNA	end	resection	in	vivo.	The	expression	of	endogenous	wild	type	NBS1	was	suppressed	with	siRNA,	and	siRNA	resistant	myc-tagged	NBS1	variants	were	ex-pressed	from	a	construct	containing	doxycycline-inducible	promoter	stably	integrated	into	chromosomal	DNA	(Fig	4A).	Downregulation	of	endogenous	NBS1	led	to	cellular	sensitivity	to	ionizing	radiation,	retention	of	MRE11	in	the	cytoplasm	and	a	DNA	end	re-section	deficiency,	as	anticipated	(Figs	4B-G,	and	EV4A	and	B).	Expression	of	wt	myc-tagged	NBS1	overcame	these	defects,	verifying	the	functionality	of	the	complementation	system	(Figs	4B-G,	and	EV4A	and	B).	To	test	for	the	involvement	of	the	FHA	and	BRCT	domains	of	NBS1	in	resection,	we	ex-pressed	wt	NBS1,	NBS1	R28A	(a	point	mutation	in	the	FHA	domain),	NBS1	K160M	(a	point	mutation	in	the	BRCT	domain),	or	the	NBS1	R28A	K160M	double	mutant	(DM)	(Cerosaletti	and	Concannon,	2003;	Hari	et	al.,	2010;	Wang	et	al.,	2013).	These	cell	lines	were	treated	with	siNBS1	for	72	h	to	knock	down	endogenous	NBS1	(Fig	4A).	For	the	last	24	h,	the	expression	of	the	complementing	NBS1	variant	was	induced	by	the	addi-tion	of	doxycycline.	Cells	were	then	irradiated	(5	Gy)	and	DNA	end	resection	was	scored	by	automated	counting	of	BrdU	foci	in	ssDNA	under	non-denaturing	conditions	or	by	counting	of	RPA2	foci	(Fig	4D-G).	The	mutation	in	either	FHA	or	BRCT	domain	led	to	an	intermediate	defect	in	DNA	end	resection	in	both	resection	assays.	The	NBS1	R28A	K160M	double	mutant	led	to	a	more	severe,	but	not	complete	abrogation,	comparable	to	NBS1	depletion	(Fig	4D-G).	Both	FHA	and	BRCT	domains	thus	individually	promote,	but	are	not	absolutely	essential,	for	the	DNA	end	resection	function	of	NBS1	in	full	agree-ment	with	our	biochemical	analysis.	
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Depletion	of	CtIP	brought	about	a	more	severe	defect	than	that	of	NBS1,	and	nearly	com-pletely	eliminated	BrdU	or	RPA2	foci	upon	IR	(Fig	4D-G).	This	confirmed	that	CtIP	is	es-sential	for	almost	all	DNA	end	resection	activity,	as	observed	previously	by	others	(Sartori	et	al.,	2007).	Furthermore,	the	depletion	of	NBS1	brought	about	lesser	defects	compared	to	CtIP	depletion	in	homologous	recombination	as	scored	by	a	DR-GFP	re-porter	assay	(Fig	EV4C-D).	Finally,	depletion	of	NBS1	did	not	completely	eliminate	sin-gle-strand	annealing	(SSA)(Fig	4I),	which	is	a	good	readout	for	extensive	DNA	end	resec-tion	(Stark	et	al.,	2004).	We	also	note	that	the	residual	SSA	activity	observed	in	the	re-porter	assay	without	NBS1	was	MRE11	dependent	(Fig	4I).		The	depletion	of	NBS1	by	siRNA	may	not	be	complete	and	may	thus	explain	the	residual	resection	we	observed.	To	this	point,	using	CRISRP/Cas9,	we	constructed	a	U2OS	hypo-morphic	NBS1ΔN	cell	line	that	expresses	low	levels	of	a	C-terminal	fragment	of	NBS1,	which	completely	lacks	the	FHA	and	BRCT	domains	(Fig	EV4F).	Similarly	as	in	mice	(Kim	et	al.,	2017),	where	a	C-terminal	fragment	of	NBS1	rescued	viability	and	ATM	acti-vation,	the	NBS1ΔN	cells	were	viable	and	grew	normally	in	the	absence	of	exogenous	DNA	damage	(data	not	shown).	MRE11	was	partially	retained	in	the	cytoplasm	in	this	cell	line,	most	likely	owing	to	the	low	expression	level	of	the	hypomorphic	NBS1	allele	that	may	not	be	sufficient	to	fully	localize	MRE11	in	the	nucleus	(Fig	EV4G).	However,	stable	expression	of	recombinant	wild	type	or	R28A	K160M	mutated	NBS1	(C-termi-nally	tagged	with	the	monomeric	GFP	analogue	mNeonGreen),	fully	restored	MRE11	nu-clear	localization	(Fig	EV4F-G).	DNA	end	resection	in	the	NBS1DN	cell	line	was	similarly	compromised	as	in	the	cells	depleted	from	NBS1	by	siRNA	(Fig	EV4E).	Consistent	with	our	siRNA-based	complementation	system,	stable	expression	of	wild	type	NBS1	in	the	NBS1DN	cell	line	efficiently	restored	DNA	end	resection	activity,	whereas	expression	of	the	R28A	K160M	double	mutant	(DM)	did	not,	indicating	that	even	though	MRE11	nu-clear	localization	is	restored	by	DM	NBS1,	resection	activity	is	not	(Fig	4H).	This	shows	that	in	contrast	to	yeast	Xrs2,	NBS1	has	functions	in	DNA	end	resection	beyond	mediat-ing	nuclear	localization	of	MRE11	and	RAD50.	Interestinlgy,	both	in	WT	and	DM	ex-pressing	cells	residual	resection	activity	is	dependent	on	CtIP	(Fig	4H),	thus	suggesting	that	CtIP	can	stimulate	resection	independently	of	NBS1	also	in	vivo.	Together,	we	demonstrated	that	limited	CtIP-dependent	DNA	end	resection	in	vivo	can	occur	without	the	FHA-BRCT	domains	of	NBS1.			Depletion	of	NBS1	impairs	nuclear	entry	of	the	MR	complex	(Fig	4B).	To	circumvent	this	problem,	we	used	the	NBS1	knockout	cell	line	that	was	complemented	with	NBS1	R28A	
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K160M	double	mutant,	which	is	compromised	in	its	interaction	with	pCtIP,	but	profi-cient	in	mediating	nuclear	import	of	MR	(Cerosaletti	and	Concannon,	2003;	Hari	et	al.,	2010;	Wang	et	al.,	2013).	Under	these	conditions,	when	NBS1	fails	to	interact	with	CtIP,	CtIP	was	still	responsible	for	most	of	the	residual	DNA	end	resection	activity	(Fig	EV4F).	Together,	we	demonstrate	that	limited	Mre11	and	CtIP-dependent	DNA	end	resection	can	occur	in	the	absence	of	NBS1	in	vivo.		
Phosphorylation	of	CtIP	is	partially	dispensable	for	stimulation	of	MR	in	the	ab-
sence	of	NBS1	NBS1	specifically	binds	phosphorylated	CtIP	(Fig	2G),	and	phosphorylation	of	CtIP	by	CDKs	is	key	for	stimulating	the	MRN	endonuclease	activity	(Anand	et	al.,	2016).	There-fore,	the	observation	that	limited	CtIP-dependent	resection	can	occur	without	the	FHA-BRCT	domains	of	NBS1	raised	the	question	whether	phosphorylation	of	CtIP	is	required	under	these	conditions.	In	Figure	2CD,	we	observed	weak	NBS1-independent	resection	
in	vitro.	To	better	define	the	mechanism	of	this	reaction,	we	modified	our	biochemical	assay	conditions	and	employed	the	extended	reaction	incubation	time	(2	h)	to	improve	the	detection	limit.	As	shown	in	Fig	5A	and	B,	we	observed	that	pCtIP	stimulated	dsDNA	cleavage	by	MR	in	the	absence	of	NBS1	in	a	concentration-dependent	manner.	Our	pre-vious	experiments	established	NBS1	as	a	reader	of	CtIP	phosphorylation,	and	the	NBS1-independent	reaction	thus	identifies	a	separate	mechanism	for	CtIP-facilitated	stimula-tion	of	MR.	Next,	we	set	out	to	test	whether	phosphorylation	of	CtIP	was	required.	We	treated	or	mock-treated	pCtIP	with	λ	phosphatase.	As	shown	previously	(Anand	et	al.,	2016),	we	observed	that	only	pCtIP	(i.e.	mock-treated),	but	not	λCtIP,	stimulated	DNA	cleavage	by	MRN	in	a	concentration-dependent	manner	(Fig	5C-E).	In	contrast,	we	ob-served	a	robust	stimulation	of	MR-dependent	DNA	clipping	by	both	phosphorylated	and	λ	phosphatase-treated	CtIP	(Fig	5C-E).	Very	similar	results	were	obtained	in	kinetic	as-says:	with	MRN,	pCtIP	was	~7-fold	more	efficient	in	promoting	the	DNA	cleavage	com-pared	to	λCtIP;	with	MR,	the	difference	was	only	~1.5-fold	(Figs	5F	and	G,	and	EV5A).	Therefore,	NBS1	appears	to	restrict	DNA	cleavage	by	MR	to	conditions	when	CtIP	is	phosphorylated.	Without	NBS1,	the	MR	cleavage	is	more	promiscuous	and	can	occur	without	CtIP	phosphorylation.	One	of	the	key	residues	in	CtIP	that	needs	to	be	phosphorylated	by	CDKs	to	allow	DNA	end	resection	during	S-phase	is	T847,	which	maps	to	a	conserved	region	that	is	equiva-lent	to	S267	of	S.	cerevisiae	Sae2	(Huertas	et	al.,	2008;	Huertas	and	Jackson,	2009).	Non-phosphorylatable	substitution	of	T847	with	alanine,	resulting	in	T847A	mutation,	
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renders	pCtIP	incapable	to	promote	DNA	end	resection	(Anand	et	al.,	2016;	Huertas	and	Jackson,	2009).	Unexpectedly,	we	observed	that	the	pCtIP	T847A	mutant	was	incapable	to	promote	both	MR	and	MRN	(Fig	5H	and	I).	This	suggested	that	the	T847A	variant	is	likely	structurally	impaired,	beyond	being	non-phosphorylatable	at	the	key	CDK	consen-sus	site.	Alternatively,	the	failure	of	pCtIP	T847A	to	promote	MR,	in	contrast	to	λCtIP,	may	stem	from	the	presence	of	other	phosphorylated	residues	in	pCtIP	T847A	that	have	an	inhibitory	function	together	with	MR.	To	test	for	this	scenario,	we	treated	pCtIP	T847A	with	λ-phosphatase,	and	observed	a	minor,	yet	statistically	significant,	rescue	of	DNA	clipping	by	MR	(Fig	EV5B	and	C).	As	wt	λCtIP	is	still	more	efficient	in	promoting	the	MR	endonuclease	than	λCtIP	T847A,	the	T847A	substitution	in	pCtIP	likely	brings	about	structural	changes	within	the	conserved	CtIP	region	that	affect	CtIP	activity	beyond	mimicking	a	non-phosphorylated	threonine.	Our	conclusion	that	the	T847A	mutation	might	bring	about	structural	defects	in	the	conserved	domain	of	CtIP	prevented	us	to	test	whether	non-phosphorylatable	CtIP	promotes	DNA	end	resection	in	the	absence	of	NBS1	in	vivo.		Together,	our	results	demonstrate	that	NBS1,	as	CtIP,	is	a	co-factor	that	stimulates	the	DNA	cleavage	efficacy	of	the	MR	complex.	Reactions	with	MRN	require	CtIP	phosphory-lation,	and	lead	to	extensive	DNA	end	resection	activity	that	is	required	for	homologous	recombination	and	SSA.	In	contrast	in	the	absence	of	NBS1,	CtIP	phosphorylation	is	par-tially	dispensable	for	the	DNA	cleavage	activity	of	the	MR	complex.			
The	physical	interaction	of	MRE11	and	RAD50	with	CtIP	does	not	require	CtIP	
phosphorylation	Our	observation	that	CtIP	was	able	to	stimulate	the	DNA	cleavage	capacity	of	the	MR	complex	prompted	us	to	define	physical	interactions	between	MRE11,	RAD50	and	phos-phorylated	or	non-phosphorylated	CtIP.	CtIP	is	known	to	interact	with	all	subunits	of	the	MRN	complex	(Chen	et	al.,	2008;	Sartori	et	al.,	2007;	Williams	et	al.,	2009;	Yuan	and	Chen,	2009);	in	accord,	we	detected	direct	interactions	between	pCtIP/CtIP	and	both	MRE11	and	RAD50	(Fig	6A	and	B).	While	phosphorylation	of	CtIP	was	absolutely	re-quired	for	its	interaction	with	NBS1	(Fig	2G),	this	was	not	the	case	for	MRE11	and	RAD50.	In	contrast,	λ	phosphatase-treated	CtIP	interacted	with	both	MRE11	and	RAD50	even	better	than	pCtIP	(Fig	6A	and	B).	We	cannot	exclude	that	the	apparent	increase	in	protein-protein	interaction	was	due	to	aggregation	of	non-phosphorylated	CtIP,	or	that	our	preparation	of	pCtIP	contained	phosphorylated	residues	that	are	not	normally	mod-ified	in	vivo,	which	could	inhibit	the	interaction	with	MRE11	and	RAD50.	Nevertheless,	
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NBS1	is	mostly	responsible	for	the	interaction	between	the	MRN	complex	and	pCtIP,	and	phosphorylation	of	CtIP	is	indispensable	for	this	interaction	(Fig	6C).	The	comparatively	weaker	interactions	of	MRE11	and	RAD50	with	CtIP	do	not	require	CtIP	phosphoryla-tion.		
NBS1	within	the	MRN-pCtIP	ensemble	promotes	endonucleolytic	activity	by	pro-
moting	access	into	dsDNA	NBS1	is	known	to	enhance	ATP-driven	dsDNA	melting	capacity	of	the	MRN	complex,	re-sulting	in	the	promotion	of	endonucleolytic	cleavage	of	DNA	near	secondary	structures	(Paull	and	Gellert,	1999).	The	differential	role	of	DNA	melting	in	the	exonucleolytic	vs.	endonucleolytic	mechanism	of	DNA	degradation	by	MRE11	allowed	Tainer	and	col-leagues	to	prepare	MRE11	inhibitors	specific	for	its	exo-	vs.	endonuclease	activity	(Shibata	et	al.,	2014).	The	endonuclease-specific	PFM03	was	designed	to	block	a	hypoth-esized	ssDNA	binding	pocket	at	a	location	separate	from	the	active	site,	in	accord	with	the	notion	that	dsDNA	melting	is	prerequisite	for	the	endonucleolytic	cleavage	by	MR	(Lafrance-Vanasse	et	al.,	2015;	Shibata	et	al.,	2014).	In	addition	to	the	endonucleolytic	cleavage	of	secondary	DNA	structures	reported	previously	(Shibata	et	al.,	2014),	we	ob-served	that	the	PFM03	inhibitor	also	efficiently	reduced	the	clipping	of	protein-blocked	DSBs	by	the	MRN	complex	in	conjunction	with	pCtIP,	while	PFM39,	an	exonuclease	in-hibitor,	did	not	(Fig	EV6A	and	B).	This	is	in	agreement	with	the	observation	that	the	PFM03	inhibitor	blocks	the	first	step	in	DNA	end	resection	in	vivo	(Shibata	et	al.,	2014).	To	learn	more	about	the	involvement	of	NBS1	in	the	DNA	clipping	reaction,	we	em-ployed	a	substrate	similar	to	that	used	by	Paull	and	colleagues	that	contains	a	preexist-ing	nick	in	the	strand	opposite	to	the	anticipated	cleavage	site	(Deshpande	et	al.,	2016).	We	reasoned	that	the	pre-existing	nick	may	reduce	the	energy	required	to	melt	dsDNA,	and	therefore	allow	the	MR	complex	to	cleave	DNA	without	NBS1.	To	this	point,	we	per-formed	kinetic	analyses	with	both	nicked	and	non-nicked	DNA	substrates,	which	had	phosphorothioate	bonds	at	the	3'-ends	to	prevent	exonucleolytic	DNA	degradation	by	Mre11	(or	MR/MRN).	We	observed	that	MRE11	alone	had	no	endonuclease	activity	on	any	of	the	substrates	tested,	with	or	without	CtIP,	as	expected	(Fig	7A	and	B,	lanes	3	and	6).	As	previously,	NBS1	promoted	the	cleavage	of	the	non-nicked	DNA	substrate	(Fig	7A	and	C)	and	pCtIP	was	essential.	In	contrast,	NBS1	was	dispensable	when	nicked	DNA	substrate	was	used	(Fig	7B,	D	and	E).	Under	these	conditions,	pCtIP	provided	a	moder-ate	stimulatory	effect,	with	or	without	NBS1	(Fig	7B,	D	and	E).	The	endonuclease	activity	was	promoted	by	a	nick	or	a	gap	in	the	top	strand,	as	a	substrate	lacking	the	top	left	
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oligonucleotide	was	not	endonucleolytically	cleaved	by	MR-CtIP	or	MRN-pCtIP	(Fig	EV7C),	and	the	DNA	cleavage	was	directed	by	a	protein	block	(Fig	EV7D).	Together,	our	results	suggest	that	NBS1,	and	to	a	lesser	extent	pCtIP,	is	dispensable	for	the	endonucle-olytic	DNA	cleavage	in	case	of	a	pre-existing	nick	opposite	to	the	cleavage	site.	We	hy-pothesize	that	a	nick	allows	the	MR	complex	to	melt	into	the	dsDNA	molecule	and	the	function	of	NBS1	to	melt	dsDNA	thus	becomes	partially	dispensable.		
Discussion	The	MRE11	nuclease	plays	critical	functions	at	DSBs	as	well	as	at	stalled,	collapsed	or	re-versed	replication	forks	(Stracker	and	Petrini,	2011).	Scheduled	activation	of	the	MRE11	nuclease	is	important	for	both	homologous	recombination	and	microhomology-medi-ated	end-joining	DSB	repair	pathways.	In	contrast,	inappropriate	MRE11	nuclease	may	result	in	illegitimate	recombination	leading	to	genome	rearrangements	or	excessive	DNA	degradation	at	challenged	replication	forks	leading	to	cell	lethality	in	certain	ge-netic	backgrounds	(Schlacher	et	al.,	2011).	Therefore,	the	activity	of	the	MRE11	nuclease	must	be	finely	controlled	and	restricted	to	situations	when	it	is	appropriate	for	genome	stability	maintenance.	MRE11	is	a	3'→5'	exonuclease	on	its	own	(Paull	and	Gellert,	1998).	In	complex	with	RAD50	and	other	co-factors,	MRE11	can	cleave	dsDNA	endonu-cleolytically	(Paull	and	Gellert,	1998,	1999).	It	is	believed	that	the	processing	of	DSBs	or	reversed	DNA	replication	forks	is	initiated	by	the	endonucleolytic	cleavage	of	the	5'-ter-minated	DNA	strand	by	MRE11	and	co-factors	(Cannavo	and	Cejka,	2014;	Garcia	et	al.,	2011;	Lemacon	et	al.,	2017;	Neale	et	al.,	2005).	Eukaryotic	cells	possess	two	key	regula-tors	of	the	MR	nuclease	complex:	CtIP/Sae2	and	NBS1/Xrs2.	In	yeast,	phosphorylated	Sae2,	but	not	Xrs2	is	required	for	the	endonucleolytic	DNA	cleavage	by	MR	(Oh	et	al.,	2016).	In	humans,	both	NBS1	and	phosphorylated	CtIP	promote	the	activity	of	the	MR	endonuclease,	revealing	that	NBS1	is	a	regulator	of	MRE11	that	is	employed	specifically	in	high	eukaryotes	(Anand	et	al.,	2016;	Deshpande	et	al.,	2016).	In	this	study,	we	define	the	mechanism	by	which	NBS1	regulates	the	MRE11	endonuclease	using	primarily	a	re-constituted	in	vitro	system.		We	show	that	NBS1	functions	as	a	sensor	of	CtIP	phosphorylation,	which	allows	the	MRE11	nuclease	activation	only	when	CtIP	is	phosphorylated	(Fig.	8A-C).	The	FHA	and	BRCT	are	highly	conserved	phosphoprotein	binding	domains,	which	mediate	the	physi-cal	interaction	of	NBS1	with	phosphorylated	CtIP	and	both	these	domains	promote	re-section	in	vitro	as	well	as	in	vivo.	Once	NBS1	senses	that	CtIP	is	phosphorylated,	it	acti-vates	the	MR	endonuclease,	which	is	dependent	on	a	direct	physical	interaction	between	
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NBS1	(residues	684-692)	and	MRE11	(Fig	8A).	We	found	that	the	FHA	and	BRCT	do-mains	of	NBS1	are	important,	but	not	absolutely	essential	for	the	MR	and	pCtIP-depend-ent	cleavage	of	dsDNA	near	protein	blocks.	More	than	the	FHA-BRCT	domains,	the	short	region	within	the	C-terminus	of	NBS1	that	interacts	with	MRE11	is	absolutely	required	for	the	NBS1	function	to	promote	the	MR	complex	in	conjunction	with	pCtIP.	In	support	of	this	model,	we	observed	a	residual	NBS1-dependent,	but	pCtIP-independent	nuclease	activity	of	the	MR	complex	in	vitro	(Fig	8C).	Without	phosphorylated	CtIP,	NBS1	still	promotes	DNA	cleavage	by	MR.	In	this	case,	the	FHA-BRCT	domains	of	NBS1	were	en-tirely	dispensable,	while	the	MRE11	interaction	region	was	required.	Nevertheless,	while	this	in	vitro	reaction	informs	us	about	the	underlying	mechanism,	we	believe	that	CtIP-independent	resection	does	not	occur	in	vivo,	as	depletion	of	CtIP	entirely	elimi-nated	resection	in	cells	in	all	assays	tested	(Fig	4)(Sartori	et	al.,	2007).	Next,	we	observed	that	in	the	absence	of	NBS1,	CtIP	still	promotes	the	endonuclease	of	MR,	albeit	to	a	lesser	extent.	This	was	observed	in	vitro	(Fig	5),	as	well	as	in	cells	upon	NBS1	depletion	or	gene	editing	that	eliminated	the	FHA	and	BRCT	domains	of	NBS1	(Fig	4).	Strikingly,	CtIP	phosphorylation	was	not	strictly	required	in	the	absence	of	NBS1	(Figs	5C-G	and	8B).	While	this	result	is	in	agreement	with	the	NBS1	function	as	a	sensor	of	CtIP	phosphorylation,	the	result	was	nevertheless	surprising,	as	it	revealed	funda-mental	differences	between	the	budding	yeast	and	human	systems.	In	yeast,	Sae2	phos-phorylation	regulates	its	physical	interaction	with	Rad50	(Cannavo	et	al.,	2018),	in	addi-tion	to	Xrs2.	Therefore,	even	in	the	absence	of	Xrs2,	Sae2	phosphorylation	is	still	fully	required	for	the	stimulation	of	the	Mre11-Rad50	endonuclease.	Using	human	proteins	instead,	we	found	that	the	phosphorylation	of	CtIP	was	largely	but	not	completely	dis-pensable	for	the	activation	of	MR	in	the	absence	of	NBS1.	This	result	might	help	explain	how	CtIP	promotes	limited	resection	in	G1.	It	is	well	established	that	CDK	and	ATM-dependent	phosphorylation	of	CtIP	is	necessary	for	the	activation	of	extended	resection	and	hence	homologous	recombination	in	S-G2	(Huertas	et	al.,	2008;	Huertas	and	Jackson,	2009).	Nevertheless,	CtIP	likely	activates	MRE11	in	MMEJ,	which	is	not	re-stricted	to	S-G2	and	requires	only	minimal	resection	(Averbeck	et	al.,	2014;	Dutta	et	al.,	2017;	Sharma	et	al.,	2015;	Truong	et	al.,	2013).	In	G1,	CtIP	is	phosphorylated	at	S327,	which	mediates	its	interaction	with	BRCA1,	but	the	G1	form	of	CtIP	will	likely	lack	other	phosphorylation	modifications	that	occur	in	S-G2	(Biehs	et	al.,	2017;	Yu	and	Chen,	2004).	We	speculate	that	this	form	of	CtIP	could	promote	the	MR	complex	in	case	the	NBS1	function	is	inhibited.	However,	we	were	unable	to	test	this	hypothesis	directly,	as	CtIP	variant	that	is	non-phosphorylatable	at	the	key	CDK	site	appears	to	be	impaired	be-yond	mimicking	a	non-phosphorylated	residue	(Fig	5H	and	I).	
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While	MRE11	and	RAD50	form	a	constitutively	interacting	dimer	of	dimers	complex,	there	are	conflicting	reports	about	the	stoichiometry	of	NBS1	within	the	MRN	complex	(Paull	and	Gellert,	1999;	Schiller	et	al.,	2012;	Trujillo	et	al.,	1998).	Furthermore,	it	has	been	reported	that	the	physical	interaction	of	NBS1	with	MR	may	be	differentially	regu-lated	in	G1	vs.	S-G2,	upon	DNA	damage	or	at	various	subcellular	locations,	such	as	at	te-lomeres	(Limbo	et	al.,	2018;	Zhou	et	al.,	2017;	Zhu	et	al.,	2000).	Specifically,	the	MR	com-plex	was	shown	to	localize	to	DSBs	in	the	absence	of	NBS1	(Limbo	et	al.,	2018),	and	NBS1	co-localized	with	MR	to	telomeres	in	S	but	not	during	interphase	(Zhu	et	al.,	2000).	Finally,	we	show	here	that	DNA	end	resection	was	strongly	reduced	but	not	completely	eliminated	in	the	absence	of	NBS1	in	cells,	despite	the	reduced	nuclear	import	of	MR,	showing	that	NBS1	may	not	be	an	obligate	component	of	the	resection	machinery	under	all	conditions.	Our	data	suggest	that	a	reduction	of	the	MR	interaction	with	NBS1	may	allow	the	complex	to	respond	to	non-phosphorylated	or	differently	phosphorylated	CtIP.	It	is	additionally	possible	that	NBS1’s	function	as	a	sensor	of	CtIP	phosphorylation	might	be	regulated	by	posttranslational	modifications	of	NBS1	(which	is	heavily	phos-phorylated)	and/or	by	other	proteins	that	could	regulate	NBS1	function.	More	research	is	needed	to	fully	understand	the	mechanisms	of	resection	in	G1,	and	the	involvement	of	MRN	and	CtIP	proteins	in	this	context.	Together,	our	results	demonstrate	that	the	MRE11-RAD50	endonuclease	is	on	its	own	restricted	and	becomes	fully	functional	in	the	presence	of	NBS1	and	phosphorylated	CtIP.	By	regulating	these	co-factors	through	mul-tiple	mechanisms,	cells	can	fine-tune	the	function	of	the	MR	endonuclease	to	optimally	promote	genome	stability	in	various	physiological	contexts.		
Material	and	Methods		
Cloning,	expression	and	purification	of	recombinant	proteins	
Recombinant	MRN,	MR	and	phosphorylated	CtIP	were	expressed	in	insect	Spodoptera	
frugiperda	(Sf)	9	cells	and	purified	by	affinity	and	ion	exchange	chromatography	as	de-scribed	previously	(Anand	et	al.,	2018;	Anand	et	al.,	2016).	MBP-NBS1-his	and	its	vari-ants,	as	well	as	MRE11-his	and	FLAG-NBS1-his	were	expressed	in	Sf9	cells	and	purified	as	described	in	detail	in	supplementary	information.	To	prepare	the	pFB-MBP-NBS1-his	expression	construct,	NBS1	was	amplified	from	pTP36	(a	kind	gift	from	Tanya	Paull,	University	of	Texas)	by	PCR	using	primers	NBS1_F	and	NBS1_R	(Tables	S1	and	S2).	The	PCR	product	was	digested	with	NheI	and	XmaI	(New	England	Biolabs)	and	cloned	into	
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corresponding	sites	of	pFB-MBP-MLH3-his	(Ranjha	et	al.,	2014).	The	preparation	of	other	NBS1	variant	expression	constructs	is	described	in	Supplementary	information.	To	prepare	FLAG-NBS1-his,	a	NBS1	sequence	that	was	codon-optimized	for	expression	in	Sf9	cells	(NBS1co)	was	purchased	from	Synbio	Technologies	and	cloned	into	BamHI-XhoI	sites	of	pFB-MBP-NBS1-his	to	create	pFB-FLAG-NBS1co-his.	To	prepare	pFB-MBP-MRE11-his,	the	MRE11	gene	was	amplified	by	PCR	from	pTP17	(a	kind	gift	from	Tanya	Paull,	University	of	Texas)	using	primers	HMRE11-FO	and	HMRE11-RE	(Tables	S1	and	S2).	The	amplified	product	was	digested	with	NheI	and	XmaI,	and	cloned	into	the	same	sites	in	pFB-MBP-Sgs1-his	plasmid	(Cejka	and	Kowalczykowski,	2010)(the	sequence	of	Sgs1	was	removed	during	this	step).		The	scheme	and	sequences	of	oligonucleotides	used	for	cloning	of	the	NBS1	fragments	and	all	other	constructs	in	this	study	are	listed	in	Tables	S1	and	S2.	Where	indicated,	1.2	μg	pCtIP	was	dephosphorylated	in	20	μl	reac-tions	with	200	units	of	λ	phosphatase	(λ-PP,	New	England	Biolabs)	in	1x	PMP	buffer	(New	England	Biolabs)	supplemented	with	1	mM	magnesium	chloride	for	15	min	at	30°C.	For	"mock"	control,	λ-PP	was	excluded	from	the	reaction.	
	
Nuclease	assays	Unless	indicated	otherwise,	nuclease	assays	(15	μl	volume)	were	carried	out	in	nuclease	buffer	containing	25	mM	Tris-HCl	pH	7.5,	5	mM	magnesium	acetate,	1	mM	manganese	acetate,	1	mM	Dithiothreitol	(DTT),	1	mM	ATP,	0.25	mg/ml	BSA	(New	England	Biolabs),	1	mM	phosphoenolpyruvate,	80	U/ml	pyruvate	kinase	(Sigma),	and	1	nM	oligonucleo-tide-based	DNA	substrate	(in	molecules).	The	reactions	were	supplemented	with	15	nM	streptavidin	(Sigma),	and	incubated	for	5	min	at	room	temperature	to	block	the	biotinyl-ated	end(s)	of	the	DNA	substrates.	The	recombinant	proteins	were	then	added	to	the	re-actions	on	ice	and	samples	were	incubated	at	37°C	for	30	min,	unless	indicated	other-wise.	Reactions	were	stopped	by	adding	0.5	μl	ethylenediaminetetraacetic	(0.5	M	EDTA)	and	1	μl	Proteinase	K	(19	mg/ml,	Roche),	and	incubated	at	50°C	for	30	min.	Finally,	15	μl	loading	buffer	(5%	formamide,	20	mM	EDTA,	bromophenol	blue)	was	added	to	all	samples	and	the	products	were	separated	on	15%	polyacrylamide	denaturing	urea	gels	(19:1	acrylamide-bisacrylamide,	Bio-Rad),	as	described	(Pinto	et	al.,	2018).	The	gels	were	fixed	in	fixing	solution	(40%	methanol,	10%	acetic	acid,	5%	glycerol)	for	30	min	at	room	temperature	and	dried	on	a	3MM	Chr	paper	(Whatman).	The	dried	gels	were	ex-posed	to	storage	phosphor	screen	(GE	Healthcare)	and	scanned	by	a	Typhoon	Phosphor	Imager	(FLA	9500,	GE	Healthcare).	Nuclease	assays	with	circular	ssDNA	substrate	(M13,	
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100	ng	per	reaction,	New	England	Biolabs)	were	carried	out	similarly	except	the	reac-tion	buffer	contained	60	mM	NaCl	and	incubation	time	was	extended	to	2	h.	The	reaction	products	were	separated	on	1.1%	agarose	gels,	which	were	stained	with	GelRed	(1:20000,	Biotium)	after	completion	of	electrophoresis	for	45	min.	The	gels	were	im-aged	with	gel	imager	(Ingenius3,	Syngene).	
	
Preparation	of	oligonucleotide-based	DNA	substrates		All	oligonucleotides	were	purified	by	polyacrylamide	gel	electrophoresis	and	purchased	from	Eurogentec.	The	labeling	of	oligonucleotides	at	the	5'-end	was	carried	out	by	T4	polynucleotide	kinase	(New	England	Biolabs)	and	[γ-32P]	ATP	(Perkin	Elmer).	The	label-ing	of	oligonucleotides	at	the	3'-end	was	carried	out	by	terminal	deoxynucleotidyl	trans-ferase	(New	England	Biolabs)	and	[α-32P]	cordycepin	5'	triphosphate,	as	described	(Pinto	et	al.,	2018).	To	prepare	quadruple	blocked	70-bp	long	DNA	substrate,	PC210	and	PC211	oligonucleotides	were	used,	as	described	previously	(Cannavo	and	Cejka,	2014).	To	prepare	single-blocked	non-nicked	substrate	(Fig	7A),	PC216C_5XSS	(GATGCATGAGGTGGAGTACGCGCCCGGGGAGCCCAAGGGCACGCCCTGGCACCCGCACCGCGGCA*C*T*T*A*C)	was	labeled	at	5'-end	and	annealed	with	PC216_5XSS	(GTAAGTGCCGCGGTGCGGGTGCCAGGGCGTGCCCTTGGGCTCCCCGGGCGCGTACTCCACCTCAT*G*C*A*T*C),	the	bold	T	represents	the	biotin	modification	and	*	represent	phos-phorothioate	linkages	between	nucleotides.	To	prepare	single	blocked	nicked	substrate	(Figs	7B	and	EV7D),	PC216C_5XSS	labeled	at	5'-end	was	annealed	with	PC216_50nt	(GTAAGTGCCGCGGTGCGGGTGCCAGGGCGTGCCCTTGGGCTCCCCGGGCG)	and	PC216_20nt_5XSS	(CGTACTCCACCTCAT*G*C*A*T*C).	To	prepare	substrate	used	in	Fig	EV7C,	PC216C_5XSS	labeled	at	5'-end	was	annealed	to	PC216_20nt_5XSS.		
Protein	interaction	assays	
To	test	for	interactions	between	recombinant	proteins,	the	"bait"	proteins	were	first	im-mobilized	on	a	resin	(either	M2	anti-FLAG	affinity	gel	[Sigma]	or	Protein	G	agarose	[Invi-trogen]	coupled	to	specific	antibodies).	The	resin	was	then	incubated	with	"prey"	pro-teins	in	binding	buffer,	washed,	and	bound	proteins	were	analyzed	by	western	blotting.	As	a	negative	control,	prey	proteins	were	incubated	with	resin	without	bait	proteins.	
Specifically,	to	detect	the	interaction	between	pCtIP	and	NBS1	variants	(Fig	2F	and	G),	1.5	μg	anti-CtIP	antibody	(61141,	Active	Motif)	was	captured	on	10	μl	protein	G	beads	
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upon	incubation	in	150	μl	PBS-T	pH	7.4	(1.37	mM	NaCl,	2.7	mM	KCl,	10	mM	Na2HPO4,	1.8	mM	KH2PO4,	0.1%	Tween	20)	for	40	min	at	room	temperature	with	continuous	rota-tion.	Next,	1	μg	recombinant	CtIP	(mock-treated	pCtIP	or	dephosphorylated	λCtIP)	was	added	and	incubated	in	60	μl	binding	buffer	(25	mM	Tris-HCl	pH	7.5,	1	mM	DTT,	3	mM	EDTA,	50	mM	NaCl,	0.2	mg/ml	BSA)	for	1	h	at	4°C	with	continuous	rotation.	The	resin	with	the	immobilized	antibody	was	washed	2	times	with	150	μl	wash	buffer	(25	mM	Tris-HCl	pH	7.5,	1	mM	DTT,	3	mM	EDTA,	80	mM	NaCl,	0.05%	Triton-X),	and	incubated	with	320	nM	NBS1	variants	in	60	μl	binding	buffer	for	1	h	at	4°	C	with	continuous	rota-tion.	The	resin	was	then	washed	3	times	with	150	μl	wash	buffer.	The	proteins	were	eluted	by	incubation	of	the	washed	resin	for	3	min	at	95°C	in	60	μl	SDS	buffer	(50	mM	Tris-HCl	pH	6.8,	1.6%	sodium	dodecyl	sulphate,	100	m	DTT,	10%	Glycerol,	0.01%	bro-mophenol	blue).	CtIP	and	NBS1	variants	were	detected	by	western	blot	using	anti-CtIP	(61141,	Active	Motif,	1:1000)	and	anti-NBS1	(NB100-143,	Novus	Biologicals,	1:1000)	antibodies.	In	assay	shown	in	Fig	6C,	90	nM	MRE11,	MR	or	MRN	was	incubated	with	im-mobilized	λCtIP	or	pCtIP	as	describe	above.	MRE11	was	detected	with	anti-MRE11	anti-body	(ab214,	Abcam,	1:1000).		
To	detect	the	interaction	between	MRE11-his	and	MBP-NBS1-his/MBP-NBS1	∆MIR-his,	or	between	MRE11-his	and	pCtIP/λCtIP	as	shown	in	Figs	EV2	and	6A,	respectively,	1.4	μg	MRE11-his	was	immobilized	on	beads	and	coupled	to	anti-MRE11	antibody	(ab214,	Abcam).	After	washing,	200	nM	MBP-NBS1-his/MBP-NBS1∆MIR-his,	or	330	nM	pCtIP/λCtIP	were	incubated	with	the	MRE11-coated	resin	in	a	60	μl	reaction	in	binding	buffer	as	described	above.	For	the	assay	shown	in	Fig	EV2E,	both	MRE11-his	and	MBP-NBS1-his/MBP-NBS1	∆MIR-his	were	detected	by	anti-his	antibody	(M091-3,	MBL,	1:10000)	by	western	blotting.		
For	the	interaction	assay	shown	in	Fig	6B,	50	ml	Sf9	cells	were	infected	with	RAD50-FLAG	baculovirus.	Cells	were	lysed	and	RAD50-FLAG	(~300	ng)	was	immobilized	on	30	μl	anti-FLAG	M2	affinity	gel.	Next,	in	a	150	μl	reaction,	330	nM	pCtIP/λCtIP	was	added	and	incubated	in	binding	buffer	for	1	h	at	4°C	with	continuous	rotation.	Beads	were	washed	4	times	with	300	μl	wash	buffer	and	proteins	were	eluted	with	wash	buffer	sup-plemented	with	3X	FLAG	peptide	(150	ng/μl,	Sigma).	Bound	RAD50-FLAG	was	detected	by	western	blotting	using	anti-FLAG	antibodies	(F3165,	Sigma,	1:2000).		
	
DR-GFP	and	SSA	reporter	assays	
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For	DR-GFP	HR	repair	reporter	assay,	DR-GFP	U2OS	cells	(gift	from	Jeremy	Stark)	were	plated	at	20’000	cells/cm2	in	6-well	plates.	After	24	h,	cells	were	treansfected	with	con-trol	siRNA	or	siRNA	against	CtIP	and	NBS1,	respectively.	48	h	after	siRNA	transfection,	cells	were	transfected	with	I-Sce1	expression	plasmid	(pCBASce).	4	h	after	transfection,	the	medium	was	replaced	and	a	second	transfection	with	siRNA	aligos	was	carried	out.	48	h	after	I-Sce1	transfection,	cells	were	analyzed	for	GFP	expression	by	flow	cytometry	on	a	LSRII	Fortessa	flow	cytometer	(BD).		
Generation	of	siRNA-based	NBS1	complementation	system	in	U2OS	cells	
To	generate	the	siRNA-based	complementation	system	for	NBS1,	the	Flp-InTM	T-RExTM	system	(Thermo	Fisher	Scientific)	was	used	according	to	the	manufacturer’s	protocols.	Briefly,	myc-tagged	full-length	NBS1	cDNAs	(wild	type	and	mutants)	were	sub-cloned	from	retroviral	expression	constructs	(Hari	et	al.,	2010)	and	ligated	into	the	pcDNA5/FRT/TO	vector.	Silent	mutations	were	introduced	in	the	siRNA	target	sequence	(see	below)	by	site-directed	mutagenesis	using	the	following	mutagenesis	primer	(sense):	5’-GTTCAAAAACAGGAGGAAGACGTGAACGTTAGAAAAAGGCCAAGG-3’.	A	Flp-In	T-REx	U2OS	cell	line	(gift	from	D.	Durocher)	was	cultured	in	Dulbecco’s	modified	Eagle	medium	(DMEM),	supplemented	with	10%	fetal	calf	serum	(FCS),	2	mM	L-glutamine	and	penicillin-streptomycin	antibiotics	under	standard	cell	culture	conditions	in	a	CO2	incu-bator	(37°C;	5%	CO2).	NBS1-myc	harboring	vectors	and	the	Flp-In	recombinase	expres-sion	plasmid	pOG44	were	mixed	in	a	1:9	ratio	and	transfected	into	the	Flp-In	T-REx	U2OS	cells.	Stable	clones	were	established	by	Hygromycin	B	(250	µg/ml)	and	Basticidin	(10	µg/ml)	selection	and	were	characterized	for	inducible	NBS1-myc	expression	by	im-munofluorescence	and	Western	blotting.		
Generation	of	the	NBS1DN	cell	line	
The	NBS1DN	cell	line	was	generated	according	to	a	protocol	published	by	the	Zhang	la-boratory	(Ran	et	al.,	2013).	The	sgRNA	target	sequence	(5’-GCGTTGAGTACGTTGTTGGA-3’)	was	cloned	into	the	PX330-U6-hSpCas9	vector	and	verified	by	sequencing.	The	tar-geting	vector	was	then	transfected	into	U2OS	cells	and	clonal	cell	lines	were	isolated	by	dilution	in	96-well	plates.	Single	clones	were	analyzed	for	NBS1	expression	by	immuno-fluorescence.	Several	clones	without	detectable	NBS1	expression	were	isolated	and	one	of	them	was	further	characterized	(data	will	be	published	elsewhere).	Frame-shift	in-ducing	insertion/deletion	(indel)	mutations	in	all	of	the	three	NBS1	alleles	present	in	U2OS	cells	were	verified	by	Sanger	sequencing	of	a	PCR-amplified	genomic	fragment	
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that	was	cloned	in	the	pCR	II	Blunt	TOPO	plasmid	(sequences	will	be	published	else-where),	indicating	that	the	FHA	BRCT	domains	coding	region	is	essentially	destroyed.	Western	blotting	however	revealed	the	presence	of	weakly	expressed	~40	kDa	protein	that	is	recognized	by	a	monoclonal	antibody	raised	against	full-length	NBS1	(Genetex,	clone	1D7,	GTX70224)	and	is	sensitive	to	downregulation	of	the	NBS1	mRNA	by	siRNA	transfection,	thus	suggesting	that	this	cell	line	expresses	low	levels	of	hypomorphic	C-terminal	fragment	of	NBS1	that	is	produced	by	internal	translation	initiation	within	the	NBS1	mRNA	using	an	open	reading	frame	generated	by	one	of	the	indel	mutations,	simi-lar	to	the	NBS1	hypomorphic	alleles	expressed	in	cell	lines	derived	from	NBS	patients	(Maser	et	al.,	2001).		
In	vivo	resection	assay	
U2OS	cell	lines	were	grown	on	coverslips	for	24	h	prior	to	treatment.	When	indicated,	cells	were	transfected	with	siRNAs	against	NBS1	(5’-GGAGGAAGAUGUCAAUGUUTT-dTdT-3’)	or	CtIP	(5’-GCUAAACAGGAACGAAUCTTdTdT-3’)	and	incubated	for	72	h.	For	heterologous	expression	of	full-length	recombinant	myc-tagged	NBS1,	doxycyclin	(1	µg/ml)	was	added	24	h	prior	to	the	experiment.	For	BrdU	staining	under	native	condi-tions,	BrdU	(10	µg/ml)	was	also	added	24	h	prior	to	the	experiment.	Cells	were	exposed	to	5	Gy	of	IR	and	then	incubated	for	3	h	at	37°C.	The	medium	was	removed,	and	cells	were	washed	with	PBS,	followed	by	a	brief	pre-extraction	on	ice	in	CSK	buffer	(100	mM	PIPES,	pH	7.0;	100	mM	NaCl;	300	mM	Sucrose;	3	mM	MgCl2;	0.4%	Triton	X-100).	Cells	were	then	fixed	in	4%	paraformaldehyde,	washed	and	prepared	for	immunofluores-cence	analysis	(see	below).		
Immunofluorescence		
Cells	were	grown	on	glass	coverslips	and	fixed	with	either	ice-cold	methanol	for	10	minutes	(for	staining	with	NBS1	and	MRE11	antibodies),	or	with	4%	buffered	formalde-hyde	(for	staining	with	all	other	antibodies)	for	15	min	at	room	temperature,	and	subse-quently	permeabilized	for	5	min	in	PBS	containing	0.2%	Triton	X-100.	Following	1h	of	blocking	in	blocking	buffer	(10%	FBS,	3%	BSA	in	PBS),	primary	antibody	incubations	were	performed	at	room	temperature	for	2	h.	Coverslips	were	washed	three	times	with	PBS	and	secondary	antibody	incubations	were	performed	for	1h	at	room	temperature	in	the	dark.	After	washing	with	PBS	for	three	times,	coverslips	were	mounted	on	glass	mi-croscopy	slides	with	Vectrashield	mounting	medium	containing	0.5	μg/ml	4’,6-dia-midino-2-phenylindole	dihydrochloride	(DAPI).	Widefiled	image	acquisition	was	done	
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on	either	a	Leica	DMI6000B	inverted	microscope	equipped	with	a	63x	Apochromat	oil	immersion	objective	(NA	1.3)	using	Leica’s	LAS-AF	software	or	on	a	Zeiss	AxioObserver	Z1	widefield	microscope,	equipped	with	a	Lumencor	SpectraX	illumination	system	and	a	63x,	1.4-NA,	i-plan	apochromat	oil-immersion	objective,	using	Zeiss’	ZEN	(blue	edition)	software.	Images	were	analyzed	using	Fiji	software	(Schindelin	et	al.,	2012).	Counting	of	BrdU	foci	or	RPA2	foci	was	done	with	a	Fiji	macro	written	for	automatic	image	analysis.	The	following	antibodies	were	used	at	the	indicated	dilutions:	rabbit	anti	NBS1	(Novus	Biologicals,	NB100-143,	1:500),	affinity	purified	sheep	anti	MRE11	(Goldberg	et	al.,	2003,	1:1000),	mouse	anti	Myc	(GeneTex,	9E10,	GTX80249,	1:250),	mouse	anti	BrdU	(Amersham/GE	healthcare,	BU-1,	RPN202,	1:100),	mouse	anti	RPA2	(Abcam,	9H8,	ab2175,	1:250).	
Western	blotting		
SDS-PAGE and western blotting were performed using total extracts prepared from cultured 
cells following standard procedures. The following antibodies were used at the indicated di-
lutions: rabbit anti ATMpS1981 (Eptimics, YE070901r, 1:5000), rabbit anti ATM (Calbiochem, 
PC-116, 1:250), mouse anti CtIP (Santa Cruz, sc-271339, 1:250), mouse anti NBS1 (GeneTex, 
1D7, GTX70224, 1:500), mouse anti RPA2 (Abcam,	9H8,	ab2175,	1:500), rabbit anti SMC1 
(Abcam, ab9262, 1:500), mouse anti RAD50 (GeneTex, 13B3, GTX70228, 1:1000), mouse anti 
MRE11 (Abcam, 12D7, ab214, 1:500), mouse anti Myc (GeneTex,	9E10,	GTX80249,	1:250),, 
mouse anti Tubulin (Sigma, DM1A, T6199, 1:2000). 
Clonogenic survival assay 
U2OS FlpIn T-REx cell lines were transfected with siNBS1 for 48h and then plated at low den-
sity in medium supplemented with 0.5 µg/ml doxycycline. 24 h later, the plates were ex-
posed to the indicated IR doses, followed by incubation for 12-14 days. Colonies were fixed 
and stained with Coomassie brilliant blue and the number of surviving colonies for each cell 
was counted. The percentage of surviving colonies for each cell line was calculated using the 
plating efficiencies of the non-irradiated cells as a reference. Survival experiments were car-
ried out in biological triplicates. 
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Figure	Legends	
	
Figure	1	-	NBS1	in	trans	with	MR	and	pCtIP	cleaves	DNA	similarly	as	MRN-pCtIP.	A A	representative	10%	polyacrylamide	gel	showing	purification	of	recombinant	MBP-NBS1-his.	The	gel	was	stained	with	Coomassie	brilliant	blue.	Amylose	flowthrough	and	eluate,	flowthrough	and	eluate	from	amylose	resin;	Ni-NTA	flowthrough	and	eluate,	
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flowthrough	and	eluate	from	nickel-nitrilotriacetic	acid	(Ni-NTA).	*	indicates	truncated	products.		B Nuclease	assay	with	MR,	MBP-NBS1-his	(denoted	here	and	thereafter	NBS1	for	brevity),	MRN	and	pCtIP	on	3’-end	labeled	70-bp	dsDNA	with	all	ends	blocked	with	streptavidin.	Samples	were	separated	on	15	%	denaturing	polyacrylamide	gel.	S,	strep-tavidin;	red	asterisk,	position	of	the	32P-label.	C Nuclease	assay	as	in	(B)	but	with	5’-end	labeled	70-bp	dsDNA.		
Figure	2	-	FHA	and	BRCT	domains	of	NBS1	are	important	for	MR-pCtIP	stimulation	
while	MRE11-NBS1	interaction	is	essential.		A A	schematic	representation	of	purified	recombinant	wild	type	NBS1	and	variants.	All	constructs	were	MBP	tagged	at	the	N-	and	his-tagged	at	the	C-terminus.	B A	representative	polyacrylamide	gel	(4-15%)	stained	with	Coomassie	brilliant	blue	showing	purified	NBS1	variants.	All	constructs	were	MBP	tagged	at	the	N-	and	his-tagged	at	the	C-terminus.	C A	representative	nuclease	assay	with	MR,	pCtIP	and	various	concentrations	of	MBP-NBS1-his	(labeled	NBS1)	on	3’-end	labeled	dsDNA.	D Quantitation	of	experiments	such	as	shown	in	(C).	Averages	shown;	n	=	5;	error	bars,	SEM.		E The	effect	of	NBS1	variants	containing	MRE11	interaction	region	(MIR)	on	the	nu-clease	of	MR	and	pCtIP.	Quantitation	of	experiments	such	as	shown	in	Fig	EV2A.	Aver-ages	shown;	n	≥	4,	error	bars,	SEM.	Statistical	significance	denotations	represent	the	analysis	between	wild	type	full-length	NBS1	(in	black)	and	the	corresponding	concen-trations	of	the	NBS1	variants;	ns	(p	>	0.05,	not	significant),	*	(p	<	0.05),	**	(p	<	0.01),	***	(p	<	0.001),	two-tailed	t-test.	F Analysis	of	pCtIP	binding	to	NBS1	variants.	Anti-CtIP	antibody	was	immobilized	on	Protein	G	agarose,	bound	to	pCtIP,	and	tested	for	interactions	with	the	indicated	NBS1	variants	(see	cartoon	at	the	top).	Western	blot	of	eluates	(left	part)	was	performed	with	anti-CtIP	and	anti-NBS1	antibodies.	Right	part	(input)	indicates	that	the	anti-NBS1	antibody	recognizes	the	NBS1	constructs	to	a	similar	level.		G Analysis	of	phosphorylated	(pCtIP,	mock-treated)	or	λ	phosphatase	treated	(λCtIP)	interactions	with	NBS1.	The	CtIP	variants	were	immobilized	on	protein	G	
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agarose,	and	incubated	with	NBS1	(see	cartoon	at	the	top).	The	western	blot	was	per-formed	with	anti-CtIP	and	anti-NBS1	antibodies.		H The	effect	of	NBS1	variants	containing	or	lacking	MRE11	interaction	region	(MIR)	on	the	nuclease	of	MR	and	pCtIP.	Quantitation	of	experiments	such	as	shown	in	Fig	EV2A	and	B.	Averages	shown,	n	≥	3,	error	bars,	SEM.	The	quantitation	of	wild	type	NBS1	(NBS1	WT,	in	black)	is	the	same	as	in	panel	(E)	and	is	shown	again	for	reference.		
Figure	3	-	Without	pCtIP,	NBS1	promotes	the	MR	endonuclease	independently	of	
its	FHA	and	BRCT	domains.	A Nuclease	assays	with	MR	and	various	NBS1	fragments	on	oligonucleotide-based	5'-end	labeled	dsDNA.	The	reaction	buffer	contained	60	mM	NaCl	and	reactions	were	in-cubated	for	2	h.	B Quantitation	of	experiments	such	as	shown	in	(A).	Averages	shown;	n	≥	3,	error	bars,	SEM.		C Nuclease	assays	with	MR	and	various	NBS1	fragments	on	M13	ssDNA.	The	reac-tion	products	were	separated	on	agarose	gels	(1.1%).	The	reaction	buffer	contained	60	mM	NaCl	and	reactions	were	incubated	for	2	h.	D Quantitation	of	experiments	such	as	shown	in	(C).	Averages	shown;	n	=	3,	error	bars,	SEM.		
	Figure	4	-	The	function	of	NBS1	in	DNA	end	resection	in	vivo.	A A	schematic	representation	of	the	NBS1	knockdown-rescue	experiments	in	U2OS	cells.	B Immunofuorescence	experiment	showing	efficient	depletion	of	NBS1	by	siRNA	and	cytoplasmic	localization	of	MRE11	in	the	NBS1-depleted	cells.	Experssion	of	myc-tagged	recombinant	NBS1	restores	MRE11	nuclear	localization.	C Western	blot	showing	efficient	depletion	of	NBS1	and	CtIP	by	siRNA	treansfection	and	expression	of	siRNA-resistant	myc-tagged	recombinant	NBS1.		D In	vivo	resection	assay	using	BrdU	staining	under	native	conditions	to	directly	de-tect	ssDNA	at	sites	of	DSBs	
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E In	vivo	resection	assay	using	RPA2	staining	as	a	marker	for	ssDNA	present	at	sites	of	DSBs	F Quantification	of	the	experiment	shown	in	D.	At	least	100	cells	were	assessed	per	condition	G Quantification	of	the	experiment	shown	in	C.	At	least	100	cells	were	assessed	per	condition	H Quantification	of	resection	activity	in	NBS1DN	cells	complemented	with	wild	type	(WT)	or	R28A	K160M	mutant	(DM)	NBS1	and	either	mock	depleted	(siCtrl)	or	depleted	of	CtIP	(siCtIP).	At	least	300	cells	were	assessed	per	condition.	Statistical	significance	was	determined	using	ordinary	one-way	ANOVA	with	Tukey’s	multiple	comparison	test.	I Quantitation	of	the	single	strand	annealing	(SSA)	reporter	assay	in	U2OS	cells.	All	cells	were	treated	with	DMSO;	where	indicated,	both	PFM03	(50	μM)	and	PFM39	(50	μM)	MRE11	inhibitors	were	added,	diluted	in	DMSO.	Averages	shown;	n	=	4,	error	bars,	SEM.				
Figure	5	-	Phosphorylation	of	CtIP	is	partially	dispensable	for	MR	stimulation	in	
the	absence	of	NBS1.	A Nuclease	assays	with	MR	and	pCtIP	on	3’-end	labeled	dsDNA,	incubated	for	2	h.		B Quantitation	of	experiments	such	as	shown	in	(A).	Averages	shown;	n	=	2;	error	bars,	range.		C Nuclease	assays	with	MRN,	MR	and	various	concentrations	of	pCtIP	(mock-treated)	or	λCtIP	on	5’-end	labeled	dsDNA,	incubated	for	2	h.		D Quantitation	of	experiments	such	as	shown	in	(C).	Averages	shown;	n	=	3;	error	bars,	SEM.		E Phosphorylated	CtIP	was	mock-incubated	(pCtIP,	lane	2)	or	treated	with	λ	phos-phatase	(λCtIP,	lane	3).	The	proteins	were	separated	on	a	10%	polyacrylamide	gel	and	stained	with	Coomassie	brilliant	blue.	
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F Quantitation	of	kinetic	nuclease	assays	with	MRN	and	pCtIP	(mock-treated)	or	λCtIP.	Averages	shown;	n	=	3;	error	bars;	SEM.	Statistical	denotations,	**	(p	<	0.01),	two-tailed	t-test.	G Quantitation	of	nuclease	assays	as	in	(E),	but	with	MR	complex	instead	of	MRN.	Averages	shown;	n	=	3;	error	bars,	SEM.	Statistical	denotations,	ns	(p	>	0.05),	two-tailed	
t-test.	H Nuclease	assays	with	MR,	MRN,	pCtIP	or	pCtIP	T847A,	as	indicated,	on	5'-end	la-beled	dsDNA.	Reactions	were	incubated	for	2	h.	I Quantitation	of	experiments	such	as	shown	in	(G).	Averages	shown;	n	=	4;	error	bars,	SEM.			
Figure	6	-	CtIP	phosphorylation	is	dispensable	for	its	interaction	with	MRE11	and	
RAD50.		A Interaction	between	MRE11	and	CtIP.	MRE11	was	immobilized	on	antibody-cou-pled	Protein	G	agarose,	and	incubated	with	pCtIP	or	λCtIP	(see	cartoon).	Western	blot	analysis	of	bound	proteins	was	performed	with	anti-MRE11	and	anti-CtIP	antibodies.		B Interaction	between	RAD50	and	CtIP.	RAD50-FLAG	was	immobilized	on	anti-FLAG	affinity	resin	and	incubated	with	pCtIP	and	λCtIP	(see	cartoon).	Western	blot	analysis	of	bound	proteins	was	performed	with	anti-FLAG	and	anti-CtIP	antibodies.		C Interaction	between	MRE11,	MR	or	MRN	and	pCtIP	or	λCtIP,	as	indicated.	Phos-phorylated	(pCtIP)	or	λ	phosphatase-treated	CtIP	(λCtIP)	were	immobilized	on	anti-body-coupled	Protein	G	agarose,	and	incubated	with	MRE11,	MR	or	MRN	complexes	(see	cartoon).	Bound	proteins	were	analyzed	by	western	blot	using	anti-CtIP	and	anti-MRE11	antibodies.			
Figure	7	-	NBS1	promotes	the	access	of	the	MRN	complex	to	dsDNA	to	promote	
DNA	cleavage.		A Representative	nuclease	assays	with	MRE11,	MR,	MRN	and	pCtIP,	as	indicated,	on	5'-end	labeled	dsDNA	with	single	streptavidin-blocked	end	(S).	The	substrate	contained	5	phosphorothioate	bonds	(PTO)	at	both	3'-ends	to	prevent	exonucleolytic	DNA	degra-dation.	Reactions	were	incubated	for	2	h.		
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B Representative	nuclease	assays	as	in	(A),	but	with	a	substrate	containing	a	nick	in	the	top	oligonucleotide	(20	nt	away	from	the	3'-end,	see	cartoon).		C Quantitation	of	experiments	such	as	shown	in	(A).	Averages	shown;	n	≥	4;	error	bars,	SEM.	D Quantitation	of	experiments	such	as	shown	in	(B).	Averages	shown;	n	=	3;	error	bars,	SEM.	E Quantitation	of	experiments	such	as	shown	in	(B).	Averages	shown;	n	=	3;	error	bars,	SEM.		
Figure	8	-	A	model	for	MRN	and	CtIP	functions	in	endonucleolytic	DNA	cleavage.	A When	phosphorylated	CtIP	and	MRN	are	present	(in	S-G2),	CtIP	phosphorylation	is	detected	by	the	FHA	and	BRCT	domains	of	NBS1	(1),	which	in	turn	promotes	DNA	cleavage	by	MR	via	direct	interaction	with	MRE11,	mediated	by	the	MRE11-interaction	region	of	NBS1	(2).	This	results	in	maximal	DNA	end	resection	activity	compatible	with	homologous	recombination.	B In	the	absence	of	NBS1	function	(see	text),	CtIP	promotes	the	nuclease	of	MR	in	a	reaction	that	is	partly	independent	of	its	phosphorylation	(3).		This	results	in	low	resec-tion	activity	of	MR,	which	may	be	sufficient	for	resection	in	G1	required	for	MMEJ.	C In	the	absence	of	CtIP,	NBS1,	through	its	MRE11-interaction	region,	but	inde-pendently	of	its	FHA	and	BRCT	domains,	promotes	the	MR	endonuclease	(4).	This	activ-ity	is	likely	very	limited	and	therefore	unlikely	to	be	physiologically	relevant.				
Expanded	View	Figure	Legends	
	
Expanded	View	figure	1	(related	to	figure	1)	A Samples	from	a	representative	purification	of	the	MR	complex	were	analyzed	by	10%	polyacrylamide	gel	electrophoresis.	The	gel	was	stained	with	Coomassie	brilliant	blue.	FLAG	flowthrough	and	eluate,	flowthrough	and	eluate	from	anti-FLAG	affinity	resin.	
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B Samples	from	a	representative	purification	of	the	MRN	complex	analyzed	by	10%	polyacrylamide	gel	electrophoresis.		C Samples	from	a	representative	purification	of	phosphorylated	CtIP	(expressed	and	purified	with	phosphatase	inhibitors)	analyzed	by	10%	polyacrylamide	gel	electropho-resis.		D Polyacrylamide	gel	stained	with	Coomassie	brilliant	blue	showing	the	partial	cleavage	of	MBP-NBS1-his	by	PreScission	protease	(PP).	The	PP	recognition	site	is	in	be-tween	the	MBP	tag	and	NBS1.	2	μg	recombinant	MBP-NBS1-his	was	incubated	for	1	h	at	4°C	with	1	μg	of	PreScission	protease.	E Nuclease	assays	with	MR	and	pCtIP	and	either	uncleaved	(left	panel)	and	partially	cleaved	MBP-NBS1	(right	panel,	~50%	cleaved)	with	PreScission	protease.	5’-end	la-beled	dsDNA	was	used	as	a	substrate.			F Polyacrylamide	gel	stained	with	Coomassie	brilliant	showing	purified	recombi-nant	MBP-NBS1-his	and	FLAG-NBS1-his.	*	indicates	truncated	product.		G Nuclease	assays	with	MR	and	pCtIP	and	either	MBP-NBS1-his	(left	panel)	or	FLAG-NBS1	(right	panel).		3’-end	labeled	dsDNA	was	used	a	substrate.			
	
Expanded	View	figure	2	(related	to	figure	2)	A Representative	nuclease	assays	with	MR,	pCtIP	and	various	MBP-NBS1-his	frag-ments	containing	MRE11-interaction	region	(MIR),	using	3’-end	labeled	dsDNA	as	a	sub-strate.		B Representative	nuclease	assays	with	MR,	pCtIP	and	various	NBS1	fragments	lack-ing	MRE11-interaction	region	(MIR)	on	3’-end	labeled	dsDNA.		C Representative	nuclease	assays	with	MR,	pCtIP	and	various	concentrations	of	MBP-NBS1∆MIR,	using	3'-end	labeled	dsDNA	as	a	substrate.		D A	representative	10%	polyacrylamide	gel	stained	with	Coomassie	brilliant	blue	showing	purified	recombinant	MRE11-his.		E Interaction	of	MRE11	with	NBS1.	MRE11	was	immobilized	on	antibody-coupled	Protein	G	agarose,	and	incubated	with	MBP-NBS1-his	or	MBP-NBS1∆MIR-his	(see	car-toon).	Bound	proteins	were	analyzed	by	western	blot	with	anti-his	antibodies.			
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Expanded	View	figure	3	(related	to	figure	3)	A Nuclease	assay	with	various	NBS1	fragments	(all	MBP	tagged	at	the	N-terminus	and	his-tagged	at	the	C-terminus)	without	MR	and	pCtIP,	using	5'-end	labeled	dsDNA	as	a	substrate.	The	reaction	buffer	contained	60	mM	NaCl	and	reactions	were	incubated	for	2	h.	B Nuclease	assay	with	MR	and	MBP-NBS1-his	(denoted	NBS1),	with	and	without	ATP	on	5'-end	labeled	dsDNA.	The	reaction	buffer	contained	60	mM	NaCl	and	reactions	were	incubated	for	2	h.	The	DNA	cleavage	reaction	requires	ATP,	in	agreement	with	ob-servations	that	ATPase-deficient	RAD50	mutants	are	incapable	of	resection	in	vivo.		C Quantitation	of	experiments	such	as	shown	in	(B).	Averages	shown,	n	=	2,	error	bars,	range.	D Nuclease	assays	with	MR	and	MBP-NBS1-his	(denoted	NBS1),	with	and	without	ATP,	using	M13	ssDNA	as	a	substrate.	The	reaction	buffer	contained	60	mM	NaCl	and	re-actions	were	incubated	for	2	h.	The	reactions	were	separated	on	1.1%	agarose	gel.	ATP	only	moderately	stimulated	M13	ssDNA	cleavage.	E Quantitation	of	experiments	such	as	shown	in	(D).	Averages	shown;	n	=	2,	error	bars,	range.	F Nuclease	assay	with	MR	and	MBP-NBS1	as	in	panel	(D),	but	with	or	without	RPA.	RPA	inhibits	M13	ssDNA	cleavage	(this	panel)	and	ATP	is	partially	dispensable	(see	pan-els	D	and	E).	In	cells,	RPA	is	ubiquitous	and	RAD50	ATPase-deficient	mutants	are	inca-pable	of	resection.	Therefore,	we	believe	that	the	M13-based	assays	do	not	accurately	mimic	the	reaction	occurring	in	vivo,	and	that	the	clipping	of	dsDNA	(see	panels	B	and	C)	is	a	better	model.		
Expanded	View	figure	4	(related	to	figure	4)	A Western	blot	of	FlpIn	T-REx	NBS1-myc	expressing	cells.	Expression	of	recombi-nant	NBS1	was	induced	for	24	h	with	doxycycline	(DOX)	prior	to	extract	preparation	B Clonogenic	survival	assay	showing	that	expression	of	siRNA-resistant	recombi-nant	NBS1	rescues	radiosensitivity	of	NBS1-depleted	cells	C Western	blot	showing	efficient	downregulation	of	CtIP	and	NBS1	in	the	HR	re-porter	assay	in	D	
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D HR	repair	reporter	assay	after	CtIP	and	NBS1	depletion.	Bars	and	error	bars	rep-resent	mean	and	SD	of	4	independent	experiments.	Statistical	significance	was	tested	by	unpaired	t-test	(p=0.0242).	E Quantification	of	resection	activity	in	wild	type	U2OS	cells	and	NBS1DN	cells.	At	least	260	cells	were	assessed	per	condition.		F Western	blot	of	extracts	prepared	from	wild	type	U2OS	cells,	NBS1DN	cells	and	NBS1DN	cells	stably	expressing	mNeonGreen	(mNG)	tagged	wild	type	(WT)	and	R28A	K160M	mutant	(DM)	full-length	NBS1,	either	mock-depleted	(siCtrl)	or	depleted	of	CtIP	(siCtIP)	by	siRNA.	Note	the	presence	of	a	presumably	hypomorphic	40	kDa	C-ter-minal	fragment	of	NBS1	(NBS1hm)	in	the	NBS1DN	cell	line.	G Immunofluorescence	of	NBS1DN	U2OS	cells	stably	expressing	mNeonGreen	(mNG)	tagged	wild	type	(WT)	and	R28A	K160M	mutant	(DM)	full-length	NBS1.	Note	that	MRE11	nuclear	localization	is	partially	impaired	in	NBS1DN	cells,	which	is	fully	rescued	by	heterologous	expression	of	NBS1.	
		
Expanded	View	figure	5	(related	to	figure	5)	A Representative	nuclease	assays	with	MR,	MRN	and	pCtIP	or	λCtIP	using	5'-end	la-beled	dsDNA.	Quantitations	of	these	and	similar	experiments	is	shown	in	Fig	5F	and	G.	Reactions	were	incubated	for	2	h.	B Nuclease	assays	with	MR	and	pCtIP	T847A	or	λCtIP	T847A	on	5'-end	labeled	dsDNA.	Reactions	were	incubated	for	2	h.	C Quantitation	of	experiments	such	as	shown	in	(E).	Averages	shown;	n	=	2;	error	bars,	range.			
Expanded	View	figure	7	(related	to	figure	7)	A Nuclease	assays	with	MRN	and	pCtIP	and	various	concentrations	of	MRE11	inhibi-tor	PFM03	(endonuclease	inhibitor)	on	5'-end	labeled	dsDNA.	B Nuclease	assays	with	MRN	and	pCtIP	and	various	concentrations	of	MRE11	inhibi-tor	PFM39	(exonuclease	inhibitor)	on	5'-end	labeled	dsDNA.	
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C Nuclease	assays	as	in	Fig	7B,	but	with	a	substrate	missing	the	top	left	oligonucleo-tide.		D Nuclease	assays	as	in	Fig	7B,	but	with	a	substrate	that	was	not	blocked	with	strep-tavidin.		
Figure 1
N
o 
pr
ot
ei
n
1      2       3      4      5      6       7      8      9      Lane
+    +    +    – +    – – MR (20 nM)
Substrate  
M
ar
ke
r
– +    – +    +    – +    pCtIP (60 nM)
– – – – – +    +    MRN (20 nM)
Endonuclease 
products 
– – +    +    +    – – NBS1 (20 nM)
nt
30
15
10
20
70 
40
50
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
CA
M
ar
ke
r
So
lu
bl
e 
ex
tra
ct
MBP-
NBS1-his
kDa 
200 
116
66
45
1        2       3        4          5        6       Lane        
Am
yl
os
e 
el
ua
te
N
iN
TA
 fl
ow
th
ro
ug
h
N
iN
TA
 e
lu
at
e
97
Am
yl
os
e 
flo
w
th
ro
ug
h
MBP: Maltose binding protein
MBP NBS1 H
is
His: Histidine
B
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
N
o 
pr
ot
ei
n
1      2       3      4      5      6       7      8      9      Lane
+    +    +    – +    – – MR (20 nM)
Substrate  
M
ar
ke
r
– +    – +    +    – +    pCtIP (60 nM)
– – – – – +    +    MRN (20 nM)
Endonuclease 
products
– – +    +    +    – – NBS1 (20 nM)
nt
30
15
10
20
70 
40
50
3’ labeled substrate        5’ labeled substrate 
*
*
S Streptavidin
Biotin
* Radioactive label
NBS1 Δ111-197
Figure 2
R
43
A
FHA BRCT1 BRCT2
20-110 111-197 219-327 684-690
MRE11-interacting 
region (MIR)
BRCT1 BRCT2 NBS1 (110-754)
NBS1 (335-754)
NBS1 (622-754)
FHA BRCT2
FHA
FHA BRCT1 BRCT2
NBS1 Δ111-335
NBS1 (1-692)
FHA
FHA BRCT1 BRCT2
NBS1 (1-110)
NBS1 (1-335)
FHA BRCT1 BRCT2 NBS1 (1-683)
FHA BRCT1 BRCT2 NBS1 ∆MIR
FHA BRCT1 BRCT2
R
28
A
H
45
A
K1
60
M
NBS1 RRHK
NBS1 WT
A B
M
ar
ke
r 
N
BS
1 
(1
-1
10
)
N
BS
1 
(1
-3
35
)
N
BS
1 
(1
-6
83
)
N
BS
1 
(1
-6
92
)
N
BS
1 
(1
10
-7
54
)
N
BS
1 
(3
35
-7
54
)
N
BS
1 
(6
22
-7
54
)
N
BS
1∆
M
IR
N
BS
1 
R
R
H
K
kDa 
200 
116
66
45
1        2        3          4        5       6        7          8        9      10        11        12        13      Lane
97
M
ar
ke
r 
N
BS
1∆
11
1-
19
7
N
BS
1∆
11
1-
33
5
kDa 
200 
116
66
45
97
+     +     – – – – pCtIP  
– – – +      +     – λCtIP 
– +     +     – +     +     NBS1
pCtIP
λCtIP
NBS1
1       2          3      4         5       6        Lane
Anti-CtIP
Anti-NBS1
G
+    +    +    +    +     +    +    +    – MR (20 nM)No
 p
ro
te
in – 30     – 0.3    1       3     10     30    30    NBS1 (nM)
1      2      3       4       5      6       7       8     9       10     Lane 
Endonuclease  
products
Substrate  
– – +    +    +     +    +    +    – pCtIP (50 nM)
C
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
1         2         3        4         5         6          7        8        9       10      11        12        13      14 15   Lane
N
BS
1
N
BS
1 
R
R
H
K
N
BS
1 
(1
10
-7
54
)
N
BS
1 
(3
35
-7
54
)
N
BS
1 
(6
22
-7
54
)
pCtIP        +      +     +      +      +      +     – – – – –
Anti-CtIP
Anti-NBS1
N
BS
1
N
BS
1 
R
R
H
K
N
BS
1 
(1
10
-7
54
)
N
BS
1 
(3
35
-7
54
)
N
BS
1 
(6
22
-7
54
)
+      – – – NBS1 WT 
– +      – – NBS1 (110-754)
– – +    – NBS1 (335-754)
– – – +   NBS1 (622-754)
Input (100 ng)
30 minutes reaction time 
30 minutes reaction time 
F
H0 5 10 15 20 25 300
10
20
30
D
N
A 
cl
ea
va
ge
 (%
)
NBS1 (nM)
DNA cleavage by MR+ 
pCtIP (without NBS1) 
0.3 1.0 3.010
.0 0.3 1.0 3.010
.0 0.3 1.0 3.010
.0 0.3 1.0 3.010
.0 0.3 1.0 3.010
.0 0.3 1.0 3.010
.0
0
10
20
30
D
N
A 
cl
ea
va
ge
 (%
 )
M
R
 +
 p
C
tIP
NBS1 variants (nM)
**
 ns
*
***
 ns**
***
*
 ns
**
 ns
*****
 ns
 ns
 ns
***
 ns
 ns
E
+ FHA
+ BRCT1/2
– FHA
+ BRCT1/2
– FHA
– BRCT1/2
FHA (R28A, R43A, 
H45A), BRCT1 (K160M)
+ FHA
– BRCT1
+ FHA
– BRCT1/2
NBS1 WT 
NBS1 (110-754)
NBS1 RRHK
NBS1 (335-754)
NBS1 Δ111-197
NBS1 Δ111-335
3 10 3 10 3 10 3 10 30 3 10 30 3 10 30 3 10 30
0
10
20
30
D
N
A 
cl
ea
va
ge
 (%
 )
M
R
 +
 p
C
tIP
NBS1 varinats (nM)
 ns
***
*** *** *** ***
*** *** *** ***
 ns
***
+ FHA  
– MIR
+ MIR
+ FHA
+ BRCT1/2
– FHA
– BRCT1/2
NBS1 (1-110)
NBS1 (1-683)
NBS1 ΔMIR
NBS1 (1-692) 
NBS1 (1-335) 
NBS1 WT 
NBS1 (622-754)
D
Figure 3
A
+    +    – +    – +    – +     – +    – +     +    – +    – +    – +     – MR (50 nM)
MR (50 nM)
NBS1 WT 
1       2      3      4       5      6               8       9      10    11    12       13     14    15     16    17    18  19     20     21    22     Lane
NBS1 
(110-754)
NBS1
(335-754)
NBS1 
(622-754)
NBS1
(1-692)
N
o 
pr
ot
ei
n NBS1 
(1-110)
NBS1
(1-335)
NBS1 
(1-683)
NBS1
∆MIR
N
o 
pr
ot
ei
n
Substrate  
Degradation 
products
NBS1 fragments containing MIR NBS1 fragments lacking MIR
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
B
2600 nt
ssDNAC
N
BS
1 
(3
35
-7
54
)
N
o 
pr
ot
ei
n
1      2      3     4      5      6     7      8       9   10       11   12    13   14    15    16   Lane
Substrate  
z 
N
BS
1
N
BS
1 
R
R
H
K
N
BS
1 
(1
10
-7
54
)
N
BS
1 
(6
22
-7
54
)
N
BS
1 
(1
-6
92
)
N
BS
1 
(1
-1
10
)
N
BS
1 
(1
-3
35
)
N
BS
1 
(1
-6
83
)
N
BS
1 
∆M
IR
Endonuclease 
products 
+   +    +   +    +   +    +    +    +           +    +    +   +   +   MR (25 nM)
N
BS
1 
∆1
11
-1
97
N
BS
1 
∆1
11
-3
35
N
o 
pr
ot
ei
n
50 50 50 50 50 50 50 50 50 50 50 50
0
10
20
30
40
D
N
A 
cl
ea
va
ge
 (%
 )
M
R
 
NBS1 varinats (nM)
+ MIR – MIR
NBS1 (1-110)
NBS1 (1-683)
NBS1ΔMIR
NBS1 (1-335) 
2 hours reaction time
NBS1 WT 
NBS1 (110-754)
NBS1 (335-754)
NBS1 (622-754) NBS1 (1-692) 
NBS1 RRHK
NBS1 Δ111-197
NBS1 Δ111-335
2 hours reaction time
2 hours reaction  time
NBS1 WT
NBS1 (335-754)
NBS1 (110-754)
NBS1 (622-754)
NBS1 (1-692)
NBS1 (1-110)
NBS1 (1-335)
NBS1 (1-683)
NBS1ΔMIR
D + MIR – MIR
50 50 50 50 50 50 50 50 50
0
20
40
60
 D
N
A 
de
gr
ad
at
io
n 
(%
)
NBS1 varinats (nM)
si
C
tr
l
si
C
tIP
si
C
tr
l
si
C
tIP
0
20
40
60
80
100
#R
PA
2 
fo
ci
 / 
pe
r c
el
l
****
****
+WT +DM
si
C
tr
l
si
C
tIP
si
N
B
S1
+W
T
+R
28
A
+K
16
0M
+D
M
0
20
40
60
#R
PA
2 
fo
ci
 / 
ce
ll
siNBS1
siCtrl siCtIP
siNBS1
+WT +R28A +K160M +DMsiNBS1
Br
dU
ATM pS1981
ATM
CtIP
NBS1
RPA2
SMC1
siC
trl
siC
tIP
+W
T
+R
28
A
+K
16
0M
+D
M
siN
BS
1
siC
trl
siNBS1
Ionizing radiation (5 Gy)C
D
F
DAPI NBS1 MRE11 Myc
si
C
trl
si
N
BS
1
si
N
BS
1
+ 
D
O
X
A
siNBS1
72 h
NBS1-myc variant 
expression, siRNA-
resistant, 24 h
IR (5 Gy)
DNA end resection 
assays
U2OS cells
B
G
Figure 4
H
siCtrl siCtIP
siNBS1
+WT +R28A +K160M +DMsiNBS1
R
PA
2
E
I
si
C
tr
l
si
C
tIP
si
N
B
S1
Si
C
tr
l
si
N
B
S1
0
2
4
6
8
G
FP
 p
os
tiv
e 
ce
lls
 (%
)
PFM03+09++
si
C
tr
l
si
C
tIP
si
N
B
S1
+W
T
+R
28
A
+K
16
0M
+D
M
0
20
40
60
#B
rd
U
 fo
ci
 / 
ce
ll
siNBS1
Figure 5
N
o 
pr
ot
ei
n
1      2      3      4     5     6      Lane
M
ar
ke
r
Endonuclease 
products
Substrate  
nt
30
15
10
20
70 
40
50
+    +    +    – MR (20 nM)
– 40   80    80   pCtIP 
(nM)
A
G
N
o 
pr
ot
ei
n
Endonuclease 
products
Substrate  
– 10   30    90   – – – 90   – pCtIP (nM)
– – – – 10    30    90   – 90    λCtIP (nM)
+ MR (20 nM)
N
o 
pr
ot
ei
n
1      2     3      4     5      6     7      8      9    10     11    12   13    14    15   16    17   18    19    20   Lane
– 10   30    90   – – – 90   –
– – – – 10    30    90   – 90 
+ MRN (20 nM)
C
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
N
o 
pr
ot
ei
n
1      2     3      4     5      6     7      8      9    10    Lane
M
ar
ke
r
Endonuclease 
products
Substrate  
nt
30
15
10
20
70 
40
50
+   +    +    – – – – – MR (20 nM)
– +    – – +    – +    – pCtIP WT (60 nM)
– – – +   +    +   – – MRN (20 nM)
– – +    – – +   – +   pCtIP T847A (60 
nM)
H
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
B
40 80
0
10
20
30
40
D
N
A 
cl
ea
va
ge
 (%
 )
pCtIP (nM)
M
R
F
0 30 60 90 120
0
10
20
30
40
50
 D
N
A 
cl
ea
va
ge
 (%
)
MRN + pCtIP
MRN + λCtIP
Time (min)
MRN
**
**
**
**
0 30 60 90 120
0
10
20
30
40
50
D
N
A 
cl
ea
va
ge
 (%
 )
Time (min)
MR
MR + pCtIP 
MR + λCtIP
 ns
 ns
 ns
 ns
10 30 90 10 30 90 10 30 90 10 30 90
0
20
40
60
D
N
A 
cl
ea
va
ge
 (%
 )
M
R
 
pCtIP or λCtIP (nM)
M
R
N
 
D
MRN + pCtIP 
MRN + λCtIP 
MR + pCtIP 
MR + λCtIP 
60 60 60 60
0
20
40
60
80
D
N
A 
cl
ea
va
ge
 (%
 )
M
R
 
pCtIP WT or pCtIP T847A (nM)
M
R
N
 
I
MRN + pCtIP WT
MRN + pCtIP T847A
MR + pCtIP WT
MR + pCtIP T847A
M
ar
ke
r
kDa 
200 
116
66
1        2         3      Lane        
97
pCtIP
λCtIP
– +
λ-phosphatase         
E
Figure 6
1      2       3      4      5     Lane
Anti-CtIP
Anti-MRE11
λCtIP
pCtIP
MRE11
+    +    +     – – MRE11
– +    – +    – pCtIP
– – +     – +    λCtIP
MRE11
pCtIP
λCtIP
C
1      2       3      4      5     Lane
Anti-CtIP λCtIP
pCtIP
RAD50-FLAG
+    +   +     – – RAD50-FLAG
– +   – +    – pCtIP
– – +     – +    λCtIP
Anti-FLAG
M
R
E1
1
M
R
M
R
N
M
R
E1
1
M
R
M
R
E1
1
M
R
N
M
R
M
R
N
1      2      3      4      5       6      7      8      9     10     11    Lane
+ pCtIP + λCtIP – CtIP
Anti-CtIP
Anti-MRE11
A B
Input (20%)
M
R
E1
1
M
R
M
R
N
Anti-MRE11
Figure 7
A
N
o 
pr
ot
ei
n
1      2      3      4      5      6      7      8       Lane
M
ar
ke
r
Substrate  
nt
30
15
10
20
70 
40
50
+    – – +    – – MRE11 (20 
nM)
– +    – – +    – MR (20 nM)
– – +    – – +    MRN (20 nM)
Endonuclease 
products 
pCtIP (50 nM)
N
o 
pr
ot
ei
n
1      2      3      4      5      6      7      8       Lane
M
ar
ke
r
Substrate  
nt
30
15
10
20
70 
40
50
+    – – +    – – MRE11 (20 nM)
– +    – – +    – MR (20 nM)
– – +    – – +    MRN (20 nM)
Endonuclease 
products 
pCtIP (50 nM)
B
D
C
5’	3’	 *	
5’	 3’	
70 bp	 S 
PTO	
PTO 	
5’	3’	 *	
5’	 3’	
70 bp	 S 
PTO	
PTO 	
5’	3’	 *	
5’	 3’	
70 bp	 S 
PTO 	
PTO	
0 30 60 90 120
0
20
40
60
 D
N
A 
cl
ea
va
ge
 (%
)
TIme (min)
MRN + pCtIP 
MR + pCtIP
5’	3’	 *	
5’	 3’	
70 bp	 S 
PTO 	
PTO	
0 30 60 90 120
0
20
40
60
 D
N
A 
cl
ea
va
ge
 (%
)
TIme (min)
MRN
MR
E
5’	3’	 *	
5’	 3’	
70 bp	 S 
PTO 	
PTO	
0 30 60 90 120
0
20
40
60
 D
N
A 
cl
ea
va
ge
 (%
)
TIme (min)
MRN + pCtIP 
MR + pCtIP
PTO ... phosphorothioate bonds 
S Streptavidin
Biotin
* Radioactive label
PTO ... phosphorothioate bonds 
S Streptavidin
Biotin
* Radioactive label
nickI
Figure 8
BA C
M
ar
ke
r
So
lu
bl
e 
ex
tra
ct
kDa 
200 
116
66
45
1       2      3      4        5      6      7      Lane        
Am
yl
os
e 
 fl
ow
th
ro
ug
h
Am
yl
os
e 
el
ua
te
Pr
es
ci
ss
io
n 
pr
ot
ea
se
97
N
iN
TA
 e
lu
at
e
pCtIP-His
N
iN
TA
  f
lo
w
th
ro
ug
h
MBP-pCtIP-His
MBP + PP
CA
M
ar
ke
r
So
lu
bl
e 
ex
tra
ct
kDa 
200 
116
66
45
1       2       3       4        5       6     Lane        
N
iN
TA
  e
lu
at
e
N
iN
TA
 fl
ow
th
ro
ug
h
FL
AG
 fl
ow
th
ro
ug
h
97
FL
AG
 e
lu
at
e
RAD50-FLAG
MRE11-His
M
ar
ke
r
So
lu
bl
e 
ex
tra
ct
kDa 
200 
116
66
45
1       2       3       4        5       6     Lane        
N
iN
TA
  e
lu
at
e
N
iN
TA
 fl
ow
th
ro
ug
h
FL
AG
 fl
ow
th
ro
ug
h
97
FL
AG
 e
lu
at
e
RAD50-FLAG
MRE11-His
NBS1
B
M
ar
ke
r
kDa 
200 
116
66
1        2        3       Lane        
97
MBP-NBS1-his
NBS1-his
– +
Prescission
protease
MBP + PP45 
D
M
ar
ke
r
kDa 
200 
116
66
1        2        3       Lane        
97
MBP-NBS1-his
FLAG-NBS1-his
45 
M
BP
-N
BS
1-
hi
s
FL
AG
-N
BS
1-
hi
s
F
Expandable view figure 1
N
o 
pr
ot
ei
n
1      2     3      4     5      6     7      8      9    10    Lane
M
ar
ke
r
Endonuclease 
products 
Substrate  
nt
30
15
10
20
70 
40
50
+    +   +    +   +   +   +    +    MR (20 nM) + pCtIP (40 nM)
– 3 10    30 – 3    10    30 MBP-NBS1-his (nM)
– PP + PP
E
5    13   12           6.8  13.6  13   % cleavage
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
N
o 
pr
ot
ei
n
1      2       3      4      5      6       7      8      9      Lane
+    +    +    – +    +    – MR (20 nM)
Substrate  
M
ar
ke
r
Endonuclease 
products 
nt
30
15
10
20
70 
40
50
+    +    +    +    +    +    +    pCtIP (50 nM)
MBP-NBS1
(nM)
FLAG-NBS1
(nM)
3     10     10     3    10     10 
G
13    16           12.8   14            % cleavage
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
*
1       2         3          4         5          Lane
Anti-his
Anti-his
MBP-NBS1/∆MIR-his
MRE11-his
+      +     +       – – MRE11
– +     – +       – NBS1 WT
– – +       – +     NBS1∆MIR
E
N
o 
pr
ot
ei
n
1      2      3      4      5      6      7      Lane
M
ar
ke
r
Substrate  
nt
30
15
10
20
70 
40
50
+    +    +    +    +   MR (20 nM)
– – 30    90     – NBS1∆MIR (nM)
Endonuclease 
products
– +    +    +    +   pCtIP (50 nM)
– – – – +   NBS1 WT (3 nM)
C
N
BS
1 
(1
-6
83
)
N
o 
pr
ot
ei
n
1      2      3     4      5      6     7      8      Lane
+    +   +   +    +    +    MR (20 
nM)
Substrate  
M
ar
ke
r
Endonuclease 
products
nt
30
15
10
20
70 
40
50
N
BS
1 
(1
-1
10
)
N
BS
1 
(1
-3
35
)
N
BS
1∆
M
IR
– +   +   +    +    +    pCtIP (50 nM)
B
M
ar
ke
r
kDa 
200 
116
66
1        2         Lane        
97 MRE11-his
45 
D
Expandable view figure 2
N
o 
pr
ot
ei
n
1      2      3     4      5      6     7      8     9     10      Lane
+    +   +   +    +    +   +    +   MR (20 nM)
Substrate  
M
ar
ke
r
Endonuclease 
products
nt
30
15
10
20
70 
40
50
N
BS
1
N
BS
1 
R
R
H
K
N
BS
1 
(1
10
-7
54
)
N
BS
1 
(3
35
-7
54
)
N
BS
1 
(6
22
-7
54
)
– +   +   +    +    +   +    +   pCtIP (50 nM)
N
BS
1 
(1
-6
92
)
A
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
+      +      +      – +      +      +      – MR (50 nM)N
o 
pr
ot
ei
n
N
o 
pr
ot
ei
n
1         2        3         4         5        6         7        8         9        10      Lane
– 25       50       50       – 25       50      50 NBS1  (nM)
Degradation 
products
Substrate  
– ATP + ATP
N
o 
pr
ot
ei
n
1      2      3     4      5      6     7      8     9     10      Lane
+    +    +   – +   +    +    – MR (25 nM)
Substrate  
Endonuclease 
products
N
o 
pr
ot
ei
n
– 5      50   50            – 5      50   50    NBS1 (nM)
– ATP + ATP
B
E
A
N
o 
pr
ot
ei
n
1      2      3      4      5      6      7      8       9     10    11    12    13   Lane
M
ar
ke
r
nt
30
15
10
20
70 
40
50
N
BS
1
N
BS
1 
R
R
H
K
N
BS
1 
(1
10
-7
54
)
N
BS
1 
(3
35
-7
54
)
N
BS
1 
(6
22
-7
54
)
N
BS
1 
(1
-6
92
)
N
o 
pr
ot
ei
n
N
BS
1 
(1
-3
35
)
N
BS
1 
(1
-6
83
)
N
BS
1 
∆M
IR
N
BS
1 
(1
-1
10
)
Substrate  
D
+      +      +      – +      +      +      – MR (50 nM)N
o 
pr
ot
ei
n
N
o 
pr
ot
ei
n
1         2        3         4         5        6         7        8         9        10      Lane
– 25       50       50       – 25       50      50 NBS1  (nM)
Degradation 
products
Substrate  
– RPA + RPA (1.23 μM)F
Expandable view figure 3
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
2600 nt
ssDNA
2600 nt
ssDNA
C
25 50 25 50
0
10
20
30
40
D
N
A 
cl
ea
va
ge
 (%
 )
– ATP + ATP
M
R
 
NBS1 (nM)
M
R
 
25 50 25 50
0
20
40
60
80
100
D
N
A 
de
gr
ad
at
io
n 
(%
)
M
R
 
NBS1 (nM)
– ATP + ATP
M
R
 
si
C
tr
l
si
C
tr
l
si
N
B
S1
si
C
tIP
0
1
2
3
4
5
%
 o
f G
FP
-p
os
iti
ve
 c
el
ls
*
+ISce1
U
2O
S
U
2O
S
U
2O
SΔ
N
0
50
100
150
200
#R
PA
2 
fo
ci
 / 
pe
r c
el
l
5 Gy
E
RAD50
NBS1
MRE11
Myc
SMC1
+ – –
– – +DOX
siCtrl
– + +siNBS1
A
0 1 2 3 4
1
10
100
IR dose (Gy)
co
lo
ni
es
 (%
 o
f c
on
tro
l) siCtrl
siNBS1
siNBS1+DOX
B
Expandable view figure 4
C D
G
CtIP
NBS1
Tubulin
si
C
trl
si
C
tIP
si
N
BS
1
MRE11NBS1-mNG
U
2O
S 
N
BS
1D
N
W
T
D
M
M
oc
k
CtIP
Tubulin
NBS1
U
2O
S 
pa
re
nt
al
U
2O
S 
N
BS
1D
N
NBS1-mNG
NBS1hm
si
C
trl
si
C
tIP
si
C
trl
si
C
tIP
NBS1-mNG
WT DM
U2OS NBS1DN
F
60 60
0
10
20
30
40
D
N
A 
cl
ea
va
ge
 (%
 )
MR + pCtIP T847A
MR + λCtIP T847A
M
R
 
pCtIP T847 or
 λCtIP T847A (nM)
*
C
Expandable view figure 5
A
– – +    – +   – – +   λCtIP (60 nM)No
 p
ro
te
in
1      2     3      4     5      6     7      8      9    10    Lane
M
ar
ke
r
Endonuclease 
products
Substrate  
nt
30
15
10
20
70 
40
50
– +   – +   – – +    – pCtIP (60 nM)
MR (20 nM) MRN (20 nM)
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
N
o 
pr
ot
ei
n
1      2     3     4      5      6     7      Lane
M
ar
ke
r
Endonuclease 
products
Substrate  
nt
30
15
10
20
70 
40
50
+    +   +    – – MR (20 nM)
– +   – +   – pCtIP T847A (60 nM)
– – +    – +    λCtIP T847A (60 nM)
B
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
Expandable view figure 7
A
N
o 
pr
ot
ei
n
1      2     3     4      5      6     7     8      Lane
50  100  200  400   –Ma
rk
er
Endonuclease 
products 
Substrate  
nt
30
15
10
20
40
50
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
D
M
SO
PFM03 (μM)
in DMSO
MRN (20 nM) + pCtIP (60 nM)
70 
N
o 
pr
ot
ei
n
1      2     3     4      5      6     7     8      Lane
50  100  200  400   –Ma
rk
er
Endonuclease 
products 
Substrate  
nt
30
15
10
20
70 
40
50
D
M
SO
PFM39 (μM)
in DMSO
MRN (20 nM) + pCtIP (60 nM)
B
3’	
*	
S 5’	
5’	
3’	70 bp	S 
S S 
N
o 
pr
ot
ei
n
1      2      3      4      5      6      7      8       Lane
M
ar
ke
r
Substrate  
nt
30
15
10
20
70 
40
50
+    – – +    – – MRE11 (20 
nM)
– +    – – +    – MR (20 nM)
– – +    – – +    MRN (20 nM)
pCtIP (50 nM)
C
N
o 
pr
ot
ei
n
1      2     3      4     5      6     7     8     9     10    Lane
Endonuclease 
products 
Substrate  
+   – +   – +    – +    – MR (20 nM)No
 p
ro
te
in
– +    – +         – +   – – MRN (20 nM)
– – +   +         – – +    +    pCtIP (50 nM)
+ STR– STR
D
5’	3’	 *	
5’	 3’	
70 bp	 S 
PTO 	
PTO	5’	3’	 *	
5’	 3’	
70 bp	
PTO 	
PTO 	5’	3’	 *	
3’	
70 bp	 S 
PTO 	
PTO 	
